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Die proximale Humerusfraktur (PHF) ist die dritthäufigste traumatische Knochenfraktur in der 
älteren Bevölkerung. Etwa 70% der dislozierten PHF, die einer chirurgischen Behandlung 
bedürfen, treten bei älteren Patienten auf. Es wird erwartet, dass sich die Inzidenz der PHF in den 
nächsten drei Jahrzehnten verdreifachen wird. Die Behandlung von PHF bleibt  problematisch, 
hauptsächlich aufgrund des Fehlens eines Konsens über die optimale Behandlungsstrategie. Leider 
ist das Ergebnis nach PHF ungünstig mit einer hohen Komplikationsrate, die zwischen 
verschiedenen Studien über bestimmte Behandlungsmethoden und zwischen verschiedenen 
Zentren variiert. 
Ziel dieser Studie ist es, die Ergebnisse der chirurgischen Behandlungsstrategien, einschließlich 
der Komplikations- und Revisionsraten, der beiden am häufigsten durchgeführten chirurgischen 
Eingriffe (winkelstabile Plattenosteosynthese (PHILOS, Synthes) und Arthroplastik) bei älteren 
Patienten mit PHF zu analysieren. Darüber hinaus wurde der klinischen Translationsprozess eines 
neuen immunmodulatorischen Therapieansatzes, der die Heilungsergebnisse für die identifizierte 
Patientengruppe verbessern kann, in dieser Arbeit initiert. 
 
Methodik: 
Es wurde eine retrospektive Analyse aller im Centrum für Muskuloskeletale Chirurgie der Charité 
–  Universitätsmedizin Berlin zwischen März 2017 und Juni 2018 wegen PHF chirurgisch 
behandelten Patienten durchgeführt, welche ein Follow-Up von mindestens sechs Monaten 
aufwiesen. Es wurden nur Patienten eingeschlossen, welche mit (PHILOS) oder einer 
Endoprothese versorgt wurden. Zusätzlich wurden die methodischen Aspekte der klinischen 
Umsetzung des  präklinischen Wissen eines immunmodulatorischen Mittel, Iloprost, in eine solide 




Es konnten 88 PHF bei 87 Probanden mit einem Durchschnittsalter von 72,9 Jahren in die Analyse 
eingeschlossen werden. Die Studie zeigte, dass die Gesamtkomplikationsrate bei 4-teiliger PHF, 
die mit PHILOS behandelt wurde, die höchsten Werte (68.8%) aufwies und damit auch höher als 
die Komplikationsrate bei endoprothetisch versorgten Patienten (19%) war. Die Tiefenanalyse 
zeigte aber auch, dass die Komplikationen nach Plattenosteosynthese einen geringeren 
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Schweregrad als die Komplikationen nach Endoprothese aufwiesen. Eine Revision erfolgte nur 
bei 8 von 19 Komplikationen (42%) in der PHILOS- im Vergleich zu 5 von 5 (100%) in der 
Endoprothetik-Gruppe. Basierend auf diesen Werten wurde ein hoher medizinischer Bedarf für 
neuartigen additive Therapien für die osteosynthetische Behandlung von höhergradigen PHF 
identifiziert.  
Der Translationsprozess der immunmodulatorischen Therapie erforderte eine detaillierte 
Bestimmung der richtigen Dosis und des Dosierungsschemas sowie die Identifizierung von Ein- 
und Ausschlusskriterien, die Auswahl repräsentativer Endpunkte und die Erstellung einer Nutzen-




Ältere Patienten mit 4-teiliger PHF, die mit PHILOS behandelt wurden, zeigten die höchste 






Proximal humerus fracture (PHF) is the third most common traumatic bone fracture in the elderly 
population. The incidence of PHF is expected to have tripled in the next three decades. About 70% 
of displaced PHF that need surgical treatment occur in elderly patients. The treatment of PHF 
remains problematic, mainly due to the lack of a consensus on the optimal treatment strategy. 
Moreover, the outcome after PHF surgery is currently unfavorable, with a high complication rate 
that varies between different studies for a given method of treatment and between different centers.  
This study aims to measure the outcome of surgical management strategies, including 
complication and revision rates, of the two most commonly performed surgical procedures (angle 
stable plate osteosynthesis (PHILOS, Synthes), and arthroplasty) in elderly patients with PHF. 
Additionally, the clinical translation process of a novel immunomodulatory approach that may 
improve the healing outcomes for the identified patient group has been established.  
Methodology 
A retrospective medical record analysis was performed at the Center for Musculoskeletal Surgery 
of the Charité - Universitaetsmedizin Berlin, where patients aged 60 years or older with PHF who 
underwent operative treatment from March 2017 to  June 2018, with either PHILOS or arthroplasty 
and with a follow-up period of at least six months, were included. In addition, the methodological 
aspects of clinically translating pre-clinical knowledge of an immunomodulatory agent, Iloprost, 
into a sound clinical trial to obtain the necessary approvals from regulatory authorities, were 
described.  
Results 
A total of 88 PHFs in 87 subjects with a mean age of 72.9 years were recorded. The study revealed 
that the overall complication rate in 4-part PHF treated with PHILOS recorded the highest values, 
68.8%, compared to 19% in arthroplasty cases. Further analysis showed that the nature of 
complications after PHILOS was less severe than the ones after arthroplasty, and revisions were 
performed in 8 out of 19 cases (42%) in the PHILOS group compared to 5 of 5 (100%) in 
arthroplasty. These observations indicated a high medical need for enhancing bone healing in 
osteosynthesis patients. 
To conduct a clinical trial with Iloprost, a detailed estimation of proper dose and dose regimen, 
identifying inclusion-exclusion criteria, selecting representative endpoints, and establishing a 
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benefit-risk assessment were performed. Regulatory approval was successfully obtained from 
relevant authorities. 
Conclusion  
Elderly patients with 4-part PHF treated with PHILOS yielded the highest complication rate and 
could benefit from the local administration of Iloprost.      
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Chapter 1 : Introduction 
 
1.1 Proximal Humerus Fractures (PHF) 
Traumatic fractures are among the most common injuries worldwide (1). In the USA, up to 25% 
of the population may suffer from musculoskeletal injury per year (2). In Germany, about 1.6 
million fractures have been reported annually (3). The fracture number is expected to increase 
because of the extended life expectancy and consecutive age-related disorders affecting the 
musculoskeletal system, such as osteoarthritis and osteoporosis (4).  
One of the most common traumatic fractures in the elderly population (>65 years old) is the 
fracture of the proximal humerus (PHF), which is ranked third after hip fracture and distal radial 
fracture, respectively (5, 6). The most common mechanism of trauma in this age group is mainly 
a simple fall from patients' height onto an outstretched hand (6, 7) (Figure 1). In Finland, a 
retrospective study on the patient (>18 years old) who suffered from PHF between the years 2006 
and 2010  showed an overall incidence of 114 and 47 fractures per 100,000 person-years in females 
and males, respectively (8). This incidence increased with age and has been linked to osteoporosis, 
which is more common in females representing 75% of cases (7). This has been confirmed in a 
study conducted between 1992 to 1996 in Edinburgh, Scotland, where the incidence of PHF was 
260 per 100000 persons/year in females aged 80 - 89 years and 109 per 100000 persons/year in 
males of the same age group (8).  
 
Figure 1: Mechanism for low energy proximal humerus fracture in elderly individuals (9) 




PHF is considered a growing challenge for health systems due to the continuous increase of cases 
every year. For instance, the incidence of PHF is expected to triple within the next three decades, 
due to the cumulative aging of the world population (10, 11). By 2050, it is expected that half of 
the German population will be over 50 years old (12). In Germany, the 2019 population profile 
shows that 18.1 million people were above 65 years old, representing 22%. According to 
predictions of the Federal Statistical Office, the number of people above 65 years old is expected 
to reach 38% by the year 2040 (13). The one-year mortality rate for PHF patients is 9.8%, while 
the five-year mortality rate is 28.2% (14). 
 
Figure 2: 14th coordinated population projection for Germany. (Statistisches Bundesamt; www.destatis.de) (13) 
 
1.2 Classification of PHF 
PHF is mainly classified according to the Neer classification (15), which is the most frequently 
used classification in addition to the AO classification. The Neer classification of PHF refers to 
the four main anatomical parts of the proximal humerus: humeral head, humeral shaft, greater 
tuberosity and lesser tuberosity. A fracture is considered displaced if there is a fragmental 
displacement of more than 1 cm or angulation of more than 45 degrees (15) (Figure 3). The fracture 
classification, according to the number of the displaced fragments, highlights the severity and 
complexity of the fracture pattern with the advancement of the classification grade (16). Although 
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the outcome of PHF could be affected by many variables such as patient age, bone quality, 
comorbidity, and fracture reduction, the link between the number of displaced fragments according 
to Neer classification has been shown to be negatively correlated with the functional outcome (17, 
18). Moreover, fracture severity, according to the Neer classification, has been previously used as 
a predictive value for the occurrence of complications (19).  
 
Figure 3: Neer Classification of proximal humerus fractures (15) 
1.3 Current clinical management strategies 
Although the management of proximal humerus fractures has been studied intensively over the 
years, it remains one of the unsolved orthopedic problems mainly due to the absence of clear 
evidence-based guidelines for treatment (20). This is reflected in the lack of a consensus on the 
optimal treatment strategy among the scientific community (17). Currently, surgeons rely on a 
combination of factors when deciding on the most suitable management strategy, such as 
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classification of the fracture, degree of fracture comminution, patient bone quality (osteoporosis), 
patient age,  physical capacity, and functional demand of the patient (21).   
1.3.1 Surgery as the first-line of treatment 
The current treatment strategy for PHF does not involve pharmacologic treatments since no drugs 
exist that are able to stimulate bone healing in fractured patients sufficiently, especially 
compromised elderly patients. Surgery remains the first-line treatment in displaced 3-part  and 4-
part PHF (22–24). Many surgical options for the treatment of PHF have been described in the 
literature, which can be categorized into fixation and arthroplasty. Fixation comprises the 
stabilization of the fragments of fractured bones by implants, such as closed reduction and 
percutaneous K wire fixation, open reduction and fixation with tension bands, bone sutures, 
cerclage wires, minimally invasive screw fixation, T-plates, intramedullary nails, and locking plate 
fixation. Arthroplasty comprises partial (hemiarthroplasty) or total (reverse or anatomical shoulder 
arthroplasty) replacement of a joint (25–28). 
PHF is common in elderly females, above all, because osteoporosis is the pathological basis of the 
fractures (29). As a result of osteoporosis, the cancellous bone trabeculae decrease in both number 
and thickness, which in turn leads to poor bone quality and a decrease in bone mass (30). The 
osteoporotic proximal humeral bone could be described as an eggshell with the lowest bone density 
being in the central part of the humeral head, which is nearly devoid of bone. Therefore, the 
management of PHF should include the evaluation of the bone mineral density and treatment of 
the possibly existing osteoporosis (31). This would also reduce the incidence of potential hip 
fractures, which increase by 500% in the first year following PHF (32). Bad bone quality leads to 
poor screw purchase and endangers the fixation stability in the gold standard of fixation, angle 
stable plate osteosynthesis (33). 
Proximal humeral locking plates 
Proximal humeral locking plates, such as the (PHILOS) plate (Synthes, Switzerland), are 
commonly used for the fixation of PHF (34).  PHILOS allows for the positioning of multiple head 
screws in predefined directions, which in turn enable a good purchase of screws in the bone. 
Moreover, the screw heads are locked in the plate producing a one unit device, giving the 
maximum possible hold of the fracture fragments after fixation (35). Osteosynthesis with the 
PHILOS is the most common fixation method for 2-part and 3-part and, in some cases, for 4-part 
fractures when it is still possible to reconstruct the humeral head (36). Although frequent 
complications after PHILOS plate osteosynthesis reached 49%, in some studies as discussed in the 
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following section (17), PHILOS has the advantage of preserving the natural anatomy of the bone 
and satisfactory functional outcome (18, 37). 
     
Figure 4: PHILOS plate (DePuy Synthes® Switzerland) (38) 
Arthroplasty 
Hemiarthroplasty is the replacement of the damaged humeral head with a metal joint prosthesis. 
The procedure has shown to be a good treatment option for complex 3-part and 4-part fractures 
(31). A randomized controlled study comparing the outcome of both hemiarthroplasty and 
conservative management in 4-part PHF showed that the range of motion was similar in both 
groups. However, the hemiarthroplasty group showed less postoperative joint pain compared with 
nonoperative conservative management (39). Nevertheless, hemiarthroplasty is considered 
inferior or at least similar in terms of the range of motion when compared to conservative non-
operative treatment of 4-part  PHF in the elderly for the long-term (39).  
1    2   
Figure 5: Hemiarthroplasty 1. GLOBAL® FX™ (DePuy Synthes® Switzerland) (40) 2. Zimmer Anatomical 
Shoulder™ Fracture System (41)  
Reverse shoulder arthroplasty (RSA) uses prosthesis components to replace the glenoid fossa as 
well as the humeral head, reversing the bearing partners of the shoulder joint (Figure 6). The design 
of the RSA enhances mechanical stability and moves the center of rotation medially and inferiorly, 
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thereby improving the function of the deltoid muscle through increasing its lever arm, which in 
turn compensates for the potential loss of rotator cuff function following the fracture (42). 
Although RSA has been shown to be an effective procedure in cases of complicated shoulder 
fractures (43), it is technically demanding, and patients are left with limited options in the case of 
implant failure (31). 
  1                               2       
Figure 6: reversed shoulder arthroplasty  
1. (DELTA XTEND™) Reverse Shoulder System (DePuy Synthes® Switzerland) (44) 2. Zimmer® Reverse System 
(45) 
1.3.2 PHF evaluation and patient considerations 
PHF typically occurs in elderly female patients after simple falls (46). These falls have a high risk 
of fracture incidence, which is reflected by the fact that the elderly with an active lifestyle suffer 
more frequently from PHF (6, 47, 48). The treatment of choice for PHF management requires a 
proper assessment with careful evaluation considering not only the fracture pattern and 
classification but also, and of high importance, the patients´ expectations. The patient evaluation 
process should begin with the patient history with particular attention on the independency level 
of the patient, the presence of previous injuries, especially rotator cuff tears and previous 
neurological injuries, and the patient's functional demands (49) and tolerability of the planned 
rehabilitation program (31). Then, the patient should be examined thoroughly, among others, for 
their general condition, presence of chronic diseases that could affect wound healing, immune 
system status, and usage of particular medication such as steroids (50). Furthermore, careful local 
examination of the affected arm, such as finding out if it is the dominant side, timing and 




A detailed osteoporosis assessment is considered a fundamental step in the patient evaluation 
process as osteoporosis is not only connected to the actual PHF but also could affect the incidence 
of possible following osteoporotic fractures (52, 53). Proper X-ray for the shoulder joint should be 
obtained in anteroposterior, lateral, and axillary views, in case of complex fracture patterns, also 
Computerized Tomography (CT) imaging, for better-visualization and planning. 
Moreover, Magnetic Resonance Imaging (MRI) could help in assessing the rotator cuff status, 
since tears accompany the PHF in up to 40% of patients (54). Rotator cuff tears at time of injury 
were found to be significantly linked to patients' functional loss at one year follow-up (55). 
1.3.3 Individualization of the treatment 
The treatment choice process for PHF in the elderly is not a simple choice and varies significantly 
from one patient to another, particularly for 4-part PHF (31). This variation could be explained by 
the absence of strict treatment guidelines for PHF treatment. Previously, the choice of treatment 
was mainly determined depending on fracture radiology and on fracture classification. However, 
this concept has been revised as depending only on these two factors was found to be unreliable 
and unreproducible (56–58). 
The controversies in treating PHF in the elderly started early in deciding whether surgical or non-
surgical treatment is a better choice for the patient. Some PHF patients have an obviously clear 
indication for surgery such as in open fracture, pathological fracture, vascular injury, or 
neurological injury which could require surgical fixation to secure the repair (36), while other 
patients have a relatively clear indication for nonsurgical treatment, such as in non-displaced 
fractures or patients with cerebral stroke or other permanent neurological impairment at the same 
fracture side. These patients would not gain benefit from surgical management. Moreover, 
conservative treatment may be preferred for unstable patients and who could only be treated 
surgically if the patient’s general condition improved (50). However, also in patients treated with 
arthroplasty, the surgeon should consider that early surgery (within the first four weeks) is an 
essential variable for the functional outcome (59, 60).  
The surgical treatment options for 4-part PHF encompass mainly angle stable plate osteosynthesis 
and arthroplasty. Murray et al. (36) describe criteria that could help in the proper selection of the 
surgical treatment for the 4-part PHF. The criteria categorize the indication into either PHILOS 
plate or primary arthroplasty with cases where both treatment modalities are indicated (figure 7). 
It has been reported that PHF patients above 50 years old with a head split injury should be treated 
with arthroplasty; this was explained by the significant damage of the articular surface that could 




1.4 Treatment outcomes and complication rates  
The outcome of fracture treatment depends on several factors that can be categorized into i) patient 
factors: age, presence of chronic diseases, bone quality, and degree of fractures, or ii) treatment-
related factors: choice of either conservative or operative treatment, the operative technique used 
and skills of the surgical team. 
The complication rate of managing PHF varies markedly between different studies for a given 
specific method of treatment. For example, the overall complication rate for locking plate fixation 
was reported to be between 9.7% and 57% (Table 1). Similarly, the complication rate of RSA was 
reported to fall between 4.8% and 68% and reached in some studies up to 75%  (62, 63). The 
reason for this difference in complication rates between studies could be attributed to the 
heterogeneity of the studies concerning several factors, such as the age of the study population, 
fracture classification, the method of outcome evaluation, and the difference in studies follow-up 
duration (64). Compared to RSA, hemiarthroplasty previously showed a higher revision rate and 
inferior results concerning pain relief, patient satisfaction, and range of motion (65–68). A 
decrease range of motion in hemiarthroplasty mainly occurs in the long run (mean 3.7 years) (69), 
which is due to possible mal-union of the humeral tuberosities (29, 70, 71). This, in turn, leads to 




   
PHILOS 
 
 Good bone quality 
 Physiologically young 
 Active patient with high 
functional demand  
 Reducible fracture pattern 
 
Gray zone: factors affecting  
the proper surgical decision  
 previous activity 
 functional demand  
 Comorbidities, including osteoporosis  
 Tolerability of revision surgery 
 Initial fracture displacement  
 Surgeon experience   
Arthroplasty 
 
 Severe shoulder 
osteoarthritis 
 Highly comminuted 
fracture 
 Decreased functional 
demands 
 Treatment of fixation 
complication 
 Head –split fracture (61) 
Figure 7: Criteria of treatment choice for the 4-part PHF 
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Table 1: Reported complication rates for locking plate fixation in proximal humerus fracture 
Study Complication rate Number of patients Median follow-up Ref. 
Aksu  et al.  9.7% 103 19 months (72) 
Koukakis et al. 15% 20 16.2 months (73) 
Agudelo et al. 19% 153 55 months (74) 
Haasters et al. 21.4% 646 12 months (75) 
Egol et al. 23.5% 51 16 months (76) 
Hepp et al. 31.3% 83 12 months (77) 
Owsley et al. 36% 53 44 months (78) 
Klug et al. 37.8% 66 12 months (64) 
Jost et al. 57% 121 22 months (79) 
 
The complication rate of managing PHF does not only vary between methods of treatment, as 
stated above, but also between different clinical centers. For instance, tertiary hospitals are known 
to receive and manage more complex referral cases that could explain higher complication rates. 
For these reasons above, it is challenging to infer accurate rates of complication of managing PHF 
from the literature. A more effective approach would be to rely on the data derived from each 
center.  
1.5 Complication patterns and associated risk factors 
1.5.1 Complication patterns 
There are different surgical procedures for PHF, particularly for complex injuries in the elderly, 
with different complications for each procedure. Nevertheless, the common possible complications 
after surgical treatment of PHF can be summarized as follows:  
a) Loss of reduction: Loss of reduction can be considered a severe complication and one of 
the most frequent causes of revision surgeries (18). It can be diagnosed with either fracture 
angulation of ≥ 10 degrees in any direction or loss of the humeral head height ≥ 5mm (80). 
It is a common complication, particularly in elderly patients, which is linked to 
osteoporosis. The prevention of loss of reduction is difficult, and loss of reduction 
frequently ends with low functional outcomes (81).                  
b) Infection: Infection after proximal humerus fracture treated with open reduction and 
internal fixation (ORIF) is a feared complication. However, the soft tissue coverage and 
good blood supply of the surgical site prevent against infection, and therefore infections 
are relatively infrequent after osteosynthesis with 2.9% of all procedures (75, 82, 83). The 
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reversed shoulder arthroplasty showed an infection rate of about 0.76% at 90 days follow-
up, which increased to 2.4% after the first year, and to 6.74% at 2-year postoperative 
follow-up (62). Infections can be divided into acute or delayed infections (84). Delayed 
infections can either occur as low-grade infections up to three years after ORIF or 
arthroplasty, and are caused by intraoperative contaminations of the implants, or as 
haematogeneous infections after many uneventful years, especially after arthroplasty. The 
latter are mostly caused by transient bacteremia. The infection management is always a 
complicated and costly process which always includes surgical intervention with the 
procedures depending on the type of infection. The required surgical procedures include 
debridement, together with either implant retention in acute infections, or removal of all 
implants in chronic infections (85, 86).  
c) Screw cut-out and long screw: penetration of the screw tip out of the medial cortex of the 
humeral head is a potential complication following surgery (87). This complication is 
common in elderly patients and linked to low bone quality and osteoporosis and occurs 
mainly in unstable fractures (78). Screws cut-out is associated with delayed healing and/or 
bone necrosis as a sequence of loss of reduction with protrusion of the upper screws into 
the joint. The screw penetration into the joint space could also occur at the time of surgery 
as a technical error (88).     
d) Pseudo-arthrosis: A relatively uncommon complication of PHF, is pseudo-arthrosis after 
ORIF. Pseudo-arthrosis is a form of nonunion, where fibrous tissue is formed between 
tissue fragments. Pseudo-arthrosis occurs more frequently with Neer type Ⅱ surgical 
humeral neck fractures, which could be explained by  excessive mobility in the fracture 
site (89). The pseudo-arthrosis treatment can be difficult due to local factors such as 
connectivity of the fracture to the synovium and the stress forces produced by muscles and 
ligaments around the fracture. Moreover, osteoporosis and cavitation of the humeral head 
pose challenges, which increase with aging. The surgical treatment of the pseudo-arthrosis 
is challenging and can lead to an unfavorable functional outcome even when treated with 
arthroplasty (89, 90).  
e) Nonunion: Nonunion is defined as the failure of bone trabeculation to cross the fracture 
gap. The clinical presentation usually includes persistent pain and loss of function of the 
shoulder. Nonunion frequently requires revision surgery (91). Therefore fracture nonunion 
has been defined by Calori et al. (92); this is the fracture that will not unite without further 
intervention.    
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f) Avascular necrosis: Avascular necrosis (AVN) of the humeral head can be defined in 
traumatic cases as bone death following deprivation of blood supply. The dead bone under 
stress forces is prone to flattening and collapse, leading to an abnormal shape of the 
humeral head and joint incongruity and is often associated with pseudo-arthrosis (31).  
g) Pseudo-paralysis: Pseudo-paralysis can be considered as one of the unsolved challenging 
complications of shoulder surgery (93). The definition of pseudo-paralysis varies in the 
literature, but it is mainly defined as the loss of active shoulder elevation more than 90 
degrees with free passive motion. Pseudo-paralysis is linked to rotator cuff tear and leads 
to low functional outcomes affecting the quality of life (93).        
h) Instability and Dislocation: Instability refers to the inability to keep the humeral head in 
the glenoid fossa (94). Instability is one of the most common and challenging 
complications that can follow arthroplasty and one of the leading causes of revision surgery 
(95, 96). The management of joint instability needs careful evaluation of the cause and 
managing the predisposing factors such as humeral shortening, excessive medialization, 
together with the proper choice of the implant and soft tissue management (96). Shoulder 
dislocation after arthroplasty can occur either early in the first three months or delayed 
(after 3 months). Early dislocation can be managed conservatively with closed reduction 
under anesthesia, providing there is no relevant biomechanical problem causing the 
dislocation (97). Delayed dislocation usually requires revision surgery after careful 
evaluation of the cause of instability (96).                  
1.5.2 Associated risk factors 
The overall healing capacity is known to be decreased in the elderly; this decrease could affect 
bone healing and lead to delayed healing or even nonhealing with its subsequent complications, as 
stated above (98). Aging is linked to many physiological changes that could affect bone healing. 
Many studies have evaluated the differences in the bone healing process between young and 
elderly and revealed several causes of delayed bone healing in the elderly (99–101). PHF is 
common in old age females and strongly linked to low bone mineral density as one of the fragility 
fractures. Its correlation with fragility is even more pronounced than the linkage with fractures of 
the hip, distal radius, or spine (29). Therefore, the management of PHF should include not only 
the evaluation of bone mineral density and treatment of the possible existing osteoporosis but also 
a thorough analysis of fragility and possibilities of prevention strategies (31, 102).  
The relationship between the immune system in the elderly and the bone healing process has been 
previously established (100, 101, 103). This link has been established concerning physiological 
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bone turnover as well as pathologically as in fragility fractures (104). The initial inflammatory 
phase of bone healing has a significant role in initiating bone healing cascade (105). Typically in 
the bone healing cascade, the initial pro-inflammatory phase is followed by the anti-inflammatory 
phase; this switch is critical for proper bone healing (99). The initial inflammatory phase of bone 
healing is a necessary step to initiate the healing cascade via sending a chemotactic signal, which 
helps to invite more cells, especially endothelial cells, to the fracture hematoma (106). This phase 
has been shown to reach its peak within the first 24 hours following bone fracture (107), then 
declines, and the inflammatory cytokines start to decrease with a predominance of the anti-
inflammatory cytokines. The upregulation of the anti-inflammatory factor expression is associated 
with an increase of expression of angiogenic factors such as heme oxygenase (HMOX), Vascular 
endothelial growth factor (VEGF), and Glucose transporter 1 (GLUT1), which are beneficial for 
bone healing (107, 108). It has been previously reported that a prolonged pro-inflammatory phase 
could impair angiogenesis and disturb the osteogenic processes leading to a delay in the healing 
progression of long bone fractures or could even lead to non-unions  (101, 107, 109, 110). 
Moreover, the initial inflammatory phase of bone healing is typically characterized by a large 
population of macrophages of the M1 phenotype, which has the ability to release cytokines that 
trigger and promote the inflammatory response (111, 112). Later in the anti-inflammatory phase 
of bone healing, the macrophages are mainly of the M2 phenotype, which releases growth factors 
and anti-inflammatory cytokines (111, 113). The switch between M1 into M2 at the proper time is 
of great value in regulating the inflammatory phase and affects the bone healing process (99). 
However, with aging, the ability to control the pro-inflammatory phase is decreased, leading to a 
prolonged and high amplitude pro-inflammatory phase, which in turn negatively affects bone 
healing (99, 114–116). 
Additionally, immunologically restricted patients such as those with autoimmune diseases or 
malignancies often suffer from delayed or insufficient fracture healing, which has been found to 
be due to the vigorous inflammatory activity on cellular and humoral levels at fracture sites (117). 
The analysis of the fracture hematomas and/or the surrounding bone marrow of these patients 
showed a significant difference in the initial inflammatory phase compared to the healthy control 
group. The immunologically restricted patients show a higher population of immune cells with 
high levels of pro-inflammatory cytokines, which could be one of the reasons that explain healing 
problems in such patients (117).  
Differences between young and old cell populations strengthen this assumption; as with aging and 
the continuous exposure to pathogens, the memory T cell population such as Terminally 
Differentiated Effector Memory CD8+T (TEMRA) increases, leading to a high CD8/ CD4 ratio. 
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CD8+T (TEMRA) cells have been proven to play a crucial role in controlling bone cells through 
specific cytokines that control the osteoclasts via specific receptor activator of nuclear factor κB 
(RANK) on the cell surface (118). These cells release RANK-ligand (RANKL) that is capable of 
stimulating osteoclasts and hence increasing bone resorption, which, as a result, delays the healing 
process (119). The link between CD8+T (TEMRA) cells and the delayed union has also been further 
proven through the finding of a high population of CD8+T (TEMRA) cells in the delayed bone 
healing fracture site (109, 120). Similarly, fractures in an animal model with a low population of 
CD8+ show enhancement of the bone healing process (101).  
Moreover, CD8+T (TEMRA) cells were found to be enriched in fracture hematomas; these cells 
were the major producers of Interferon gamma /Tumor necrosis factor-alpha (IFN ɣ/ TNFα), which 
inhibit osteogenic differentiation and the survival of human mesenchymal stromal cells (101). On 
the other hand, the T regulatory (Treg) subtype revealed a positive impact on both wound and bone 
healing (121–125). Additionally, bone healing capacity was found to be improved in the (Treg) 
high population animal model (121–125). Therefore, balancing the CD4+ Tregs / CD8+ effector 
memory cell ratio could enhance the local fracture milieu and control the inflammatory phase in a 
way that could benefit the bone healing process in elderly patients (107, 126).  
1.6 Novel concepts in bone regeneration 
PHF in elderly patients has shown increased rates of healing delays with the consequence of 
fracture complications. As given in detail above, the complication rate due to deficient bone quality 
in elderly patients has reached up to 57% for surgically treated patients (79). Therefore, these 
patients exhibit a high medical need for a biological solution. Immunomodulatory therapy has 
emerged as a potential therapeutic strategy that can benefit fracture patients with unfavorable 
immune responses. Such therapies are expected to reduce the risk of delayed bone healing in 
fracture patients with a potential dysregulation of the immune reaction and altered immune cell 
compositions in the fracture site through downregulating CD8+ cytotoxic cells, which has a 
potentially unfavorable effect on bone healing. Moreover, immunomodulatory therapy reduces the 
TNF-α and IFN- γ secretion of T cells and further supports macrophage polarization towards an 
anti-inflammatory type. In other words, immunomodulatory therapy aims to downregulate the 
inflammatory phase, which is known to be of high amplitude and long duration in this specific age 
group due to an over-reactive immune response (101, 120, 127).  
In recent years, the potential role of Iloprost as an immunomodulatory agent was found to be 
promoting an anti-inflammatory and immunosuppressive effect (128, 129). Iloprost is a synthetic 
analogue of prostacyclin PGI2, a product of the cyclooxygenase pathway metabolizing arachidonic 
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acid constitutively in human cells, which dilates systemic and pulmonary arterial vascular beds.  
The U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA) 
approved Iloprost in 2004 and 2003, respectively, for the treatment of Primary Pulmonary 
Hypertension (PPH). Moreover, Iloprost has been used in cases of Buerger disease (thromboangitis 
obliterans), scleroderma, and ischemia (130), in addition to severe pain caused by sickle cell crisis, 
Reynaud phenomenon and systemic lupus erythematosus. Iloprost acts by causing vasodilatation 
in the microcirculation, reducing the capillary permeability, preventing the adhesion of 
thrombocytes, improving the viscosity of distal vessels, and reducing the generation of oxygen 
free radicals and leukotrienes (131, 132). Furthermore, the drug has been previously used as an 
off-label treatment for bone marrow edema in initial cases of osteonecrosis and showed promising 
therapeutic results (132–135).  
The immune-modulatory effect of Iloprost has been investigated in the context of bone 
regeneration (100). In vitro studies confirmed the immune-modulatory properties of Iloprost and 
the postulated positive osteogenic effect (100). In a proof of concept in vivo study, the local 
Iloprost application in a mouse osteotomy during the early bone healing phase showed a positive 
impact on bone healing, where Iloprost within a fibrin-based release system was inserted during 
surgery into an osteotomy gap of a mouse to delay the release of Iloprost to the surgical site (100). 
This delay allowed the initial pro-inflammatory phase to continue and initiate the healing cascade 
of the local fracture milieu (107, 126). Another preclinical experiment in a sheep model was 
performed, where Iloprost was applied in a hydrogel scaffold during surgery in the bone drilled 
hole (136). No adverse effects nor local toxicities were observed with the local application of 
Iloprost in this large animal model, which could be evidence for the local safety of Iloprost 
application. 
1.6.1 The potential benefits of Iloprost in bone healing 
According to the performed and published preclinical findings to date, the benefits of Iloprost as 
an immune-modulatory agent in inducing bone regeneration can be summarized as follows:  
1.6.1.1 Immunomodulatory Effects of Iloprost on cytokines:  
Iloprost reduced the concentration of secreted IFNγ and TNFα of T cells creating a favorable 
milieu for MSC differentiation. This effect has been tested in vitro on murine MSCs in two 
different Iloprost doses (300 nM and 3 μM) (100). Both cytokines (IFNγ and TNFα) have a 
significant role as signaling molecules in bone repair, particularly in the early fracture healing 
phase with overly high amounts of them negatively affecting bone repair by diminishing the 
formation of the mineralized matrix by MSCs (101). 
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1.6.1.2 Immunomodulatory Effects of Iloprost on CD8+ T cells:  
The preclinical data showed that the presence of 3 μM Iloprost affects the isolated CD8+ T cells 
leading to a decreased secretion of IFNγ and TNFα (100). CD8+ T cells are one of the primary 
producers of pro-inflammatory cytokines in the early bone repair phase (101). 
1.6.1.3 Immunomodulatory Effects of Iloprost on macrophages:  
Iloprost led to the downregulation of pro-inflammatory and the upregulation of anti-inflammatory 
cytokines by MΦ, M1, or M2 polarized macrophages. Macrophages are responsible for the 
clearing of the cell debris through early infiltrating the fracture area and are necessary for the 
recruitment of further cells adverse for the progression of the healing cascade due to their secreted 
cytokine profile (4).  
1.6.1.4 Iloprost showed no negative impact on the osteogenic and chondrogenic differentiation 
capacity of MSCs:  
MSCs are the precursor cells for both cartilage-producing chondrocytes and bone-forming 
osteoblasts. Iloprost showed no negative effect on the osteogenic capacity of MSCs when added 
to monolayers of MSCs that have been cultured for 14 days in osteoinductive media (100). 
Additionally, Iloprost did not hinder the chondrogenic differentiation of MSCs (100). 
1.6.1.5 Iloprost promotes fracture healing in vivo: 
Iloprost embedded in a fibrin clot (used as a delayed-release system) was inserted during surgery 
in an osteotomy gap of a mouse osteotomy model system. This delayed release allows the initial 
pro-inflammatory phase to proceed and to initiate the healing cascade. Micro-computed 
tomography (μCT) analysis 21 days post-surgery showed an improved healing outcome of the 
mice receiving Iloprost in comparison to the control group (an increase of both bone volume and 
total callus volume as well as the ratio of bone volume/total callus volume) (100). Additionally, 
histomorphometric (IHC) analysis of the tissue distribution around the gap after 21 days in the 
Iloprost treated group showed a significantly higher amount of mineralized bone and cartilage 
tissue (100). Finally, IHC analysis of about three days post-osteotomy showed the starting shift of 
the pro-inflammatory into the anti-inflammatory phase in the mouse osteotomy model system 
(100).  
1.6.1.6 Iloprost effect on bone microcirculation: 
Iloprost has also been previously used as an off-label treatment for bone marrow edema in early 
cases of osteonecrosis and showed promising therapeutic results (132–135, 137). Iloprost has been 
successfully used as an IV infusion to treat AVN safely with minor and totally reversible side 
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effects (138). Iloprost vasodilator effect is found to enhance microcirculation and increase local 
blood flow (138) by causing vasodilatation in the microcirculation, reducing the capillary 
permeability, preventing the adhesion of thrombocytes, improving the viscosity of distal vessels, 
and reducing the generation of oxygen free radicals and leukotrienes (131, 132). 
1.7 Clinical trial approval  
The process of clinical trial approval falls under the Directive 2001/20/EC (139) of the European 
Parliament and Council, which regulates the performance of clinical trials in humans while 
protecting their rights and dignity according to the Declaration of Helsinki (140, 141) and the good 
clinical practice guidelines (142). In order to obtain approval for a clinical trial in humans, the 
applicant should demonstrate a profound benefit-risk assessment and guarantee participant rights, 
well-being, and data protection throughout the entire clinical trial. Two simultaneous application 
processes need to be initiated and approved before starting a clinical trial, one at the ethics 
committee and the other at the relevant competent authority, which in this case was the Federal 
Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte 
BfArM) because the immunomodulatory agent Iloprost is a small molecule drug.  
1.7.1 Ethics committee 
The state office for health and social affairs (Landesamt für Gesundheit und Soziales (LAGeSo)) 
sets up the ethics committee of the state of Berlin to evaluate clinical trial applications, according 
to the German regulation for approval, and implements the clinical trial with medicinal products 
in humans (GCP-V) (143) and section 42 of the Medicinal Products Act (Arzneimittelgesetz – 
AMG) (144). Within ten days of receiving the application, the ethics committee is responsible for 
informing the sponsor that either a correct application has been received, or for asking the sponsor 
to resubmit any missing documents within fourteen days. The review timeline is one month 
between the formally completed submission and the first oral consultation for a Phase 1 mono 
center clinical trial. During the evaluation process of the application, the ethics committee can only 
request additional information from the sponsor once. The deadline for the ethics committee 
response is postponed until the additional information is received. Then, the ethics committee 
sends their reasoned assessment to the sponsor and the competent higher federal authority. 
The following is the list of documents that are required to be submitted to the ethics committee in 
both paper and electronic forms: 
1. Cover letter, which should include study data such as the name of the study, EudraCT 
number, sponsor name, study center, the list of all documents, their version and date, in 
addition to the confirmation that the electronic and paper versions are identical. 
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2. Application checklist form (list of all required documents) according to the 12th 
amendment to the AMG and the GCP-V (143, 145).  
3. EudraCT: (European Union Drug Regulating Authorities Clinical Trials database). This is 
a registry of the interventional clinical trials operated by the European Medicines Agency 
and used by the member state competent authority to approve and monitor the clinical trial.     
4. Module 2 (general overview of the trial) 
5. EudraCT confirmation letter sent to the applicant after initiation of the new EudraCT 
6. Sponsor responsibility (principal investigator authorization letter)  
7. Study protocol German summary that should include the general outlines of the study 
protocol 
8. Study protocol:  this is one of the most crucial documents in the clinical trial application. 
It should include: a) general data as the name of the study, sponsor, monitor, principle 
investigator, and the clinical lab or other technical departments. b) background information 
of the investigational product. c) study objectives d) study design e) participants selection 
criteria f) assessment of efficacy and safety as well as study statistics g) data access, 
handling, record keeping, quality control measurements, ethics considerations, financial 
overview, and publication policy (GCP) (142)     
9. Risk-benefit assessment 
10. Investigational Brochure (IB) and the professional drug information: the IB should include 
all relevant clinical and nonclinical data on the investigational drug and the rationale for 
conducting the clinical trial. In the case of using previously marketed drugs, the summary 
of product characteristics should be attached. In the case of using an already marketed drug 
in a new indication, the IB should be prepared to be specific for the new use. (GCP) (142)  
11. Patient information sheet and the informed consent form. Both documents should be 
written in easily understandable language for the patients with detailed information about 
the trial, mentioning the possible risks and benefits of the investigational drug in addition 
to including all data rights and responsibilities of the participants, and providing data on 
study insurance. 
12. The study insurance documents. According to the (AMG), the insurance for the clinical 
trial should be at least 500000 Euro per study participant, which can be paid in cases of 
permanent disability or death in connection with clinical trials (144) 
13. Principle investigator and sub-investigator (deputy) qualification documents and 




14. Study financial cost estimate: an overall study financial overview  
1.7.2 Federal Institute for Drugs and Medical Devices (BfArM) 
According to the GCP-V (143) and the section 40- 42 of the (AMG)(144), the relevant competent 
authority in this trial is the Federal Institute for Drugs and Medical Devices (BfArM) because the 
investigational drug (Iloprost as an immunomodulatory agent) is a small molecule drug. After 
receiving the application, the BfArM will respond to the sponsor within ten days either that their 
application is complete, or inform the sponsor of any missing document. The sponsor then has 
fourteen days to resend the missing document to the BfArM. Starting from the date of formally 
complete clinical trial submission, the BfArM has 30 days to evaluate the application and either 
approve or object to the conduct of the clinical trial. In the event of objecting to the trial, the 
sponsor has 90 days to reply to the BfArM objections by submitting additional 
documents/information. Finally, the BfArM has fifteen days to give the final decision of the whole 
application process. The ethics committee will also receive a copy of this final BfArM decision.  
The following list of documents should be prepared in accordance with the European Commission 
2010/C82/01 (146) and submitted to the BfArM in both paper and electronic forms: 
1. Cover Letter 
2. EudraCT and confirmation letter for the EudraCT number 
3. Study protocol 
4. Investigator’s Brochure (IB) 
5. Investigator Medicinal Product Dossier (IMPD). This is a critical document in the clinical 
trial application; the IMP is defined in the Directive 2001/20/EC (139) Article 2 (d) as  “a 
pharmaceutical form of an active substance or placebo being tested or used as a reference 
in a clinical trial, including products already with marketing authorization but used or 
assembled (formulated or packaged) in a way different from the authorized form, or when 
used for an unauthorized indication, or also when used to gain further information about 
the authorized form (139)”. This means that even the reference products such as placebo 
should be considered as an IMP. The given data should include all data regarding the 
general information and structure of the drug, detailed manufacturing data including 
materials and steps control, characterization, impurities, control of the drug substance, 
reference standards, container closure system, and data on the drug stability (147). In the 
case of using a previously authorized drug, in the clinical trial, it is sufficient to mention 
the marketing authorization number and marketing authorization holder, and it is possible 
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to refer to the data of preclinical and clinical use of the drug as well as data regarding the 
toxicology and safety profile of the drug (147). 
6. Risk and benefit assessment 
This section includes a detailed analysis of the data, either clinical or nonclinical, to 
elaborate on the benefits and risks of using the investigational product. Risk and benefit 
assessment should mention any previously terminated clinical trial for safety issues 
discussing the cause of termination. The safety margin should also be mentioned by 
discussing the clinical relevance of any previously available clinical or non-clinical data 
(146). Moreover, it is essential to prove that the expected benefits outweigh the possible 
potential risks during the whole trial period during the trial (139).   
7. Non Investigational Medicinal products dossier (Non-IMPD) if applicable. The non-IMPD 
is a medicinal product, for example, that is used in the trial as a concomitant (148).  
8. Good manufacturing practice (GMP) (Manufacturing authorization as a proof for GMP 
compliance, this is only applicable if the previously authorized drug will not be used in its 
original form) 
9. Labeling (if applicable) 
10. Administrative Documents (sex distribution, further treatment, data protection declaration, 
costs declarations) 
11. Scientific Advice (if applicable) 
12. Genetically Modified Organisms (GMO) (if applicable) 
1.8 Aims of the study  
Regardless of the availability of different treatment options for PHF, the choice of the optimal 
management approach remains debatable, especially for patients above 60 years of age with 3-part  
and 4-part fractures, (149). Notably, members of this age group more frequently have a more 
experienced adaptive immune system than a younger collective, and the accompanied unfavorable 
immune response can lead to delayed bone healing, as discussed above (100, 107, 126). Moreover, 
the analysis of all surgical procedures outcomes and complication rates significantly differ 
between different treatment centers. Analyzing the outcome results and complication rate of 
current surgical management strategies for elderly patients with PHF in a leading academic center, 
where a high competence in fracture management with osteosynthesis and arthroplasty is present, 
could serve as a reference for the evaluation of the respective surgical techniques. The correlation 
of patients with a certain fracture pattern with the outcome can assist in considering their enrolment 
in an intervention study for the planned immunomodulatory therapy. 
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As such, the aim of this thesis was divided into two stages. The first aim focused on measuring the 
outcome of surgical management strategies, including complication and revision rates, of the two 
most commonly performed surgical procedures (angel stable plate osteosynthesis and arthroplasty) 
in elderly patients with PHF via a retrospective database analysis performed at the Center for 
Musculoskeletal Surgery at the Charité - Universitätsmedizin Berlin. This enabled us to identify 
the group of patients who could gain benefit from novel therapeutic approaches improving bone 
healing. The second part of this study focused on translating a scientifically sound novel 
immunomodulatory approach from the pre-clinical stage to phase I, Ⅱa clinical trial that could 
improve the healing outcomes for the identified group of patients. 
Specific aims: 
1. To perform a literature review and identify gaps in knowledge regarding the current 
management strategies of PHF, the magnitude of complications following PHF 
management in elderly patients, and the potential benefits of immunomodulatory therapies.  
2. To assess which surgical procedure for PHF is associated with lower complication and 
revision rates based on fracture classification. 
3. To propose a novel therapeutic approach (immunomodulatory therapy) by translating 
preclinical data into a clinical trial that may help in improving the outcome of elderly 




Chapter 2 : Methods 
The methodology of the study is divided into two sections. The first section focuses on a literature 
review and retrospective medical record analysis. This research was based on a review of data 
from patients suffering from PHF who had been surgically treated between March 2017 and June 
2018 at the Center for Musculoskeletal Surgery (CMSC) of the Charité - Universitätsmedizin 
Berlin. The second part focuses on the development of a scientifically sound clinical testing 
strategy for an investigational immunomodulatory molecule.  
2.1 Retrospective study 
2.1.1 Literature review and formulating the research question  
Research on PHF is known to lack comparative trials and having been performed on heterogeneous 
study populations, leading to the unavailability of reliable clinical recommendations (150). On the 
other hand, there is a rapid expansion in the literature for PHF focusing on new technologies and 
procedures. Due to this diversity in treatment strategies, and a substantial lack of clinical reports 
describing complication rates, particularly in elderly patients, performing a literature review to 
map and fill in the apparent knowledge gaps was seen as a necessary first step. PubMed, EMBASE, 
and MEDLINE databases were searched for the literature reporting on elderly patients treated 
surgically for (PHF). The search specifically focused on prospective clinical studies and 
retrospective observational studies investigating the outcome and the complication rate of surgical 
treatment of PHF. The search words included (proximal humer* fracture OR humer* head fracture 
AND age* OR elder* OR old* AND surgical OR surgery OR operat* AND treatment OR 
management OR outcome). The search scope was narrowed to the English language literature and 
from 2000 to 2020 (08.09.2020). Search filters applied were full text available, clinical trial, 
randomized control trial, review, and exclude duplication. The inclusion criteria were randomized 
control studies and cohort studies that recruited patients 60 years old or above, received operative 
treatment for PHF with any comparator, and follow up of at least one year. The exclusion criteria 
were case report studies (Figure 8).  
The literature review has led to the formulation of the following study questions: 
“Which group of patients in the elderly population with PHF have the least favorable clinical 
outcomes after surgical intervention?” and:  
“Which clinical trial design investigating a local immunomodulatory therapy would have the 
potential of showing an effect on the outcome of PHF treatment?” 
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The research question was designed following the ‘PICOT’ model as follows: 
 the patient population being studied: elderly patients suffering from PHF 
 the intervention: treated with arthroplasty or ORIF (PHILOS)  
 the condition: PHF based on Neer classification  
 the outcome of interest: complication rates 
 the timing of the analysis: six months after surgery 
The complications discussed in this study were of Grade 2 or higher according to the surgical 
complication classification described by Dindo et al. (151). According to Dindo et al., Grade 1 is 
any abnormal postoperative deviation, which includes events of minor risk that does not require 
therapy except simple medications such as analgesic, antipyretic or antiemetic. Grade 2 includes 
complications that may need either medical treatment (except the simple medications of Grade 1) 
or prolonged hospital stay by two times more than the average hospital stay of a similar procedure. 
Grade 3 encompasses any complication that could require invasive intervention. In contrast, Grade 
4 is any complication that could lead to organ resection or permanent disability, and Grade 5 is 
any complication that could lead to death (151). 
2.1.2 Study center 
This study was based on single-center retrospective research. The study was carried out in the 
Center for Musculoskeletal Surgery (CMSC) of the Charité - Universitätsmedizin Berlin, 
considered as one of the largest orthopedic and trauma centers in Germany. The center is located 
at both Charité campuses, Mitte and Virchow Klinikum, with more than 8200 hospital admission 
cases and about 8500 surgical procedures every year.  
2.1.3 Study design 
This study is a retrospective medical record review study. The center’s medical database was 
searched for all primary treatments of PHFs between March 2017 and June 2018 in patients aged 
60 years or older utilizing the corresponding ICD-10 codes. All individual patient identifiers were 
removed, and patients' data were given a serial identification number (anonymized) when included 
in the study. 
2.1.4 Patient selection 
Patients aged 60 years or older with PHF who underwent operative treatment from March 2017 
until June 2018 were the target group for this study. One hundred and five patients with PHF were 




S42.20: Fracture proximal humerus (part unspecified) 
S42.21: Head fractures including proximal epiphysis, proximal humerus fracture with two to four 
fragments 
S42.22: Surgical neck 
S42.23: Anatomical neck 
S42.24: Greater tuberosity 
S42.29: Other and multiple parts, includes: lesser tuberosity 
2.1.4.1 Inclusion criteria  
(1) A diagnosis of PHF 
(2) Received surgical treatment with arthroplasty (hemiarthroplasty or reverse shoulder 
arthroplasty (RSA)) or ORIF with PHILOS (Synthes® GmbH, Switzerland)  
(3) Completed a follow-up of six months  
(4) Complete medical records were available 
2.1.4.2 Exclusion criteria 
(1) Age younger than 60 years old 
(2) Treatment for PHF other than arthroplasty or PHILOS 
(3) Follow-up of less than six months or insufficient data 
All surgically treated PHF cases were screened to preserve the observational nature of the study. 
X-rays were used for the radiological confirmation of the diagnosis (PHF) and the identification 
of fracture-healing complications. Complications were also retrieved from the medical record 
database. All available X-rays and CT scans were analyzed carefully, together with the radiological 
reports as well as the medical file registry. 
2.1.5 Data search and collection 
Data collection, curation, and evaluation were performed between November 2018 and February 
2019. Data search was performed on the medical records included in the (SAP, Walldorf, 
Germany) system of the Charité. The management plan for all eligible patients was carefully 
reviewed within the electronic medical file. The relevant data were collected with particular 
attention to the data of physical examination reports, operative notes, discharge letters, follow up 
visit reports, radiological examinations, and radiological reports. 
The observed cases were mainly evaluated for: 
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 method of treatment 
 fracture classification 
 complications  
 revision surgeries  
2.1.6 Patients data verification  
Data collection was performed in an Excel database sheet explicitly designed for this study. During 
data collection, patients were listed in the sheet according to the date of the surgical procedure 
they had received. The diagnosis included in the medical record for each patient and the performed 
surgical procedure were checked against the X-ray documentation.  
The X-rays of eligible patients were examined to determine the fracture classification following 
the Neer fracture classification.  Cases that were classified according to the AO classification were 
changed to the equivalent Neer classification. Finally, information on the course of fracture healing 
and associated complications were extracted and confirmed from the outpatient follow-up visits, 
the follow-up radiographs, and operation reports for the revision surgeries. 
2.1.7 Statistical analysis 
The collected data were imported from the Excel sheet to STATA statistical program for statistical 
analysis. The applied version of the Stata program was Stata version 15.1 (Copyright 1985-2017 
StataCorp LLC- College Station, Texas 77845 USA). The logistic regression model allowed the 
identification of the possibility of complication occurrence with specific fracture classification. 
Moreover, it enabled the quantitative detection of the strength of association between the factor 
(fracture type and surgical technique) and the predictor (rate of complications). To determine the 
statistical significance of these correlations, an odds ratio with a confidence interval of 95% was 
calculated. P values of 0.05 were considered statistically significant. 
 
2.2 The development of a scientifically sound clinical testing strategy   
After identifying patients who were associated with a high rate of complications and high revision 
rate, the existing pre-clinical knowledge established about the local Iloprost application as an 
immunomodulatory agent, was translated into a clinical strategy to test this novel therapeutic 
approach in a human study. The clinical trial aims at investigating the safety of the local use of the 
drug and its ability to improve healing outcomes in PHF patients by modulating the prolonged and 
excessive pro-inflammatory reaction after fracture and surgery. The preclinical studies performed 
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by researchers at the Berlin Institute of Health Centre for Regenerative Therapies (BCRT) 
confirmed the immune-modulatory properties of Iloprost and the postulated positive osteogenic 
effect (100). Used locally to enhance bone healing, Iloprost is registered under patent number 
EP17188813.4 (European patent number) and CH833/2016 (Charité number). The work 
performed within the framework of this thesis focused on the utilization of the performed 
nonclinical studies to determine the clinical testing strategy in PHF patients, which eventually 
enabled us to submit a formally complete clinical trial application to the authorities and obtain the 
necessary approvals. To reach this aim, several aspects related to translational research and clinical 
trial design had to be investigated and devised. As part of this thesis study, the following tasks 
were identified:  
1) performing a literature review on the immunomodulatory characteristics of Iloprost  
2) determining the dose regimen (duration of treatment, formulation, and method of delivery)  
3) determining the dosage of the investigational drug  
4) selecting clinically representative endpoints and relevant controls 
5) identifying inclusion and exclusion criteria to assess the suitability of the study population 
6) identifying potential harms (adverse event (AE) and serious AE (SAE)) 
7) establishing clinical monitoring measures during the infusion of Iloprost 






Chapter 3 : Results 
3.1 Literature review  
The search yielded 1776 records in PubMed and 1396 records in Medline and EMBASE, which 
were reduced to 311 after applying the search filters. Subsequently, abstract screening of the 311 
records was conducted using the inclusion /exclusion criteria, further reducing the number to 64 
search results. 
Records identified through 
PubMed searching  
































Records for abstract screening after applying 
filters (n = 311) 
Full-text articles assessed 
for eligibility (n = 64) 
Meta-analysis, systematic review, case 
report, patients below 60y, follow-up 
less than 12 months:         
 PubMed (n = 155) 
 Medline and EMBASE (n = 87) 
 Repeated in PubMed (n = 5) 
Studies that fulfill 
inclusion criteria (n = 34) 
Full-text articles excluded (n= 30) 
 Patients age less than 60y (n = 15) 
 Clinical trial protocol (n = 4) 
 Not focusing on outcome and 
complication rate (n= 7) 
 Case series (n= 1) 
 Full text not in English (n= 1) 
 Full text not available (n= 2) 
Records identified through Medline 
and EMBASE searching  
(n = 1396) 
Records excluded with search 
filters:  
PubMed (n = 1581) 
Records excluded with search 
filters:  
Medline and EMBASE (n = 1280) 
Figure 8: Flow diagram of the literature review  
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Full-text screening removed 30 records for not meeting the inclusion criteria, leaving 34 studies 
to be included in the analysis. In the 34 studies, a total of 2121 patients were included, out of which 
471 were treated with PHILOS, 158 were treated with an intramedullary nail, 271 were treated 
with pinning either percutaneous or with tension band, 254 were treated with Hemiarthroplasty, 
and 375 were treated with reversed shoulder arthroplasty (RSA). The remaining patients received 
various treatments, such as different plates (other than PHILOS) or treated conservatively as a 
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et al. (153) 
2020 RCT 
 To compare the outcome of 
RSA / angular stable plate 
124 104       60   64 24 




To introduce a new technique - 
PHILOS augmented with 
titanium mesh  
22 22      22     
12–
16 
Lopiz Y. et 
al. (155) 2019 RCT 
To compare the outcome RSA / 
conservative for 3- or 4-part 
PHFs 
62 59 32         30 12 
Launonen 
A.P. et al. 
(156) 
2019 RCT 
PHILOS / conservative for 
displaced type 2 PHF 88 72 44      44    24 
Hengg C. et 
al. (157) 
2019 RCT 
PHILOS / PHILOS with screw 
augmentation 
67 55     28  27    12 
Plath J E. et 
al. (158) 
2019 RCT 
To compare the outcomes of 
IMN / PHILOS 
81 55   28    27    12 
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Blonna D. et 
al. (159) 2019 
Retrospective 
Cohort study 
To report the outcomes for pins 
stabilized with an external 
fixator for PHF / - 
188 188  188         24 
Chivot M. et 




 (RSA) / conservative in  
displaced 3-part or 4-part PHF 60 60 32         28 24 




PHILOS / PHILOS combined 
with fibular allograft in 3- and 
4-part PHF 
42 42      21 21    12 
Simovitch 






To evaluate tuberosity union in 
RSA for 3- and 4-part PHF 55 55          55 33.7 





IMN / PHILOS/ conservative  
198 184 43  72    69    24 
Chen A.C. et 
al. (164) 2017 
Retrospective 
cohort study 
To evaluate the efficacy of 
PHILOS using the anterolateral 





      21    24 
Sebastia-





Primary RSA / RSA as a 
revision (only primary cases are 
included) 
30 30          30 
24-
60 
Obert L. et 




To compare the outcomes RSA 





Youn S.M. et 
al. (167) 2016 
Retrospective 
cohort study 
To evaluate the outcomes of 
uncemented RSA  
 




Forcada E. et 
al. (168) 
2014 RCT 
To compare the outcomes of 




et al. (169) 2014 RCT 
Deltoid-split approach / 
deltopectoral approach for 
PHILOS 
120 90        90   12 
De Kruijf M. 
et al. (170) 2014 
Retrospective 
analysis 
To assess the safety and 
functional outcome of surgical 
treatment of PHF in the elderly. 
64 64  15 4   5 24  16  12 
Liu Q. et al.  
(171) 
2013 Clinical trial 
To compare the outcome of the 
TRIGEN IMN / PHF 
64 54   54        12 
Cuff D.J. et 
al. (172) 
2013 Cohort study 
To compare the outcome of 
Hemiarthroplasty / RSA  







Age effect on patients outcome 
of PHILOS treated PHF  45 45       45    12 





2-year outcomes of PHILOS / 
Hemiarthroplasty for PHF  
32 27       13  19  24 
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Boons H. W. 
et al.  (175) 2012 RCT 
Outcome after 4-part PHF 
treated either conservative / 
Hemiarthroplasty. 
50 50 25        25  12 
Carbone S. et 
al. (176) 
2012 Clinical trial 
The outcome of 2 different types 
of percutaneous pinning in 3- or 
4-part PHF in the American 
Society of Anesthesiologists 
score 3 or 4 
58 54  58         24 
Fjalestad T. 
et al. (177) 
2012 RCT 
PHILOS / conservative for 
displaced 3- and 4-part PHF 
50 48 25      25    12 
Liu Z. et 
al.(178) 
2011 RCT 
 PHILOS / minimally invasive 
injectable graft 
50 50     29  21    
12- 
25 
Olerud P. et 
al. (39) 2011 RCT 
2-year outcome of 
Hemiarthroplasty /conservative 
for a displaced 4-part PHF 
55 49 25        24  24 
Voigt C. et 
al.  (179) 2011 RCT 
Polyaxial /non polyaxially 
locked screw-plate systems 56 48    20   28    12 
Fjalestad T. 
et al.  (180) 2010 RCT 
To evaluate the costs and health 
outcome for surgical / 
conservative   
50 50 25      25    12 
Klein M. et 
al. (181) 
2008 Clinical trial 
To evaluate the outcome after 
RSA 




et al. (78) 2008 
Retrospective 
review 
To assess the radiographic and 
clinical results of treating PHF 
with PHILOS 
21 21       21    12 
Krause F.G. 
et al. (182) 
2007 Clinical trial 
To compare the stability of 2 
fixation techniques for the 
tuberosities in 3- or 4-part PHF 
treated with Hemiarthroplasty. 
58 58         58  32 
Agorastides 
L. et al. (183) 2007 RCT 
To compare 2 mobilization 
regimens after Hemiarthroplasty 
for acute 3- and 4-part PHF.  
59 49         59  12 
Cheng-
Chang Lu et 
al. (184) 
2004 Clinical trial 
To investigates intramedullary 
pinning with tension-band 
wiring for PHF treatment 
10 10  10         20.6 
Total    2121 1935 251 271 158 20 57 48 471 90 254 375  


















































































































Fraser A.N. et al. (153) 60 18.3 1      9   2 2 
One periprosthetic fracture 
One rotator cuff tear 
Launonen A.P. et al.(156) 44 7       2    1 One peri-implant fracture 
Hengg C. et al.(157) 27 38.9  2   2 2 3 1 1  1 One soft tissue complication 
Plath J. E. et al. (158) 27 34.3  3  6 2  12    4 
One axillary n. lesion 
One adhesive capsulitis 
Two tuberosity resorptions 
Zhao L. et al.(161) 21 33.3     1  3    3 Three cases of head collapse 
Wei Ge et al.(163) 69 26.1 2 4   6 3 14   1   
Chen A. C. et al. (164) 21 43     2  7      
De Kruijf M. et al.(170) 24 8.3 2            
Shulman B.S. et al.(173) 45 22.2           10 Unspecified ten complications 
Cai M. et al.(174) 13 23 1         1 2 Two fixation failures 
Fjalestad T. et al.(177) 25 60       7    8 
One hardware failure 
Seven partial axillary n. injuries 
Liu Z. et al. (178) 21 28.6  3   2  2      
Voigt C. et al. (179) 28 29.2  3 5 1 5  13      
Fjalestad T. et al. (180) 25 40 2    21      1 One fixation failure 
Owsley K.C. et al. (78) 21 57  9     9      
Total  471 
Avr. ± SD 
31.3 ± 15.2 
8 24 5 7 39 5 81 1 1 4 32  
45 
 

































































































Plath J. E. et al. (158) 28 33.3  2  4 1  2  3 
Three tuberosity 
resorptions 
Wei Ge et al. (163) 72 18.1  2   2  6  3 
Three rotator cuff 
injuries  
De Kruijf M et al.(170) 4 -            
Liu Q. et al. (171) 54 14.8 1  2  1 1 1 2    































































































Sebastiá-Forcada E. et al.(168) 30 30    
 
 
 1  8 
One intraoperative fracture, one stiffness, six 
proximal migration 
De Kruijf M. et al.(170) 16 12.5      1  1 One axillary n. damage 
Cuff D.J. et al.(172) 23 39     1   9 Nine tuberosity resorptions 





1  4 
Two fixation failures, one dislocation,  
One loosening  
Boons HW et al. (175) 25 32 2 5 4 
 
 
   4 
One head stem separation 
One proximal implant migration 
Two partial GT resorptions 
Olerud P. et al. (39) 24 29.2  5  1    3 
One complete resorption of GT  
Two partial resorptions of the GT 
Krause F.G. et al. (182) 58 25.9  13  
 
 
   27 
12 tuberosity resorptions, one periprosthetic 
fracture, eight stiffnesses, two partial axillary n. 
injuries, two aseptic loosenings, two cable wire 
breakages 
Agorastides I. et al. (183) 59 20.4  4     6    
Total 254 
Aver. ± SD 
25.5 ± 9 
3 27 4 1 1 3 6 54 
 




















































Fraser A.N. et al. (153) 64 10.9  2  2 3 One glenoid fracture, two periprosthetic fracture 
Lopiz L. et al. (155) 30 6.7    2  Two suprascapular nerve injuries 
Chivot M. et al. (160) 28 7   2   
 
Simovitch R.W. et al. (162) 55 12.7 
 
 
  1 20 
One ulnar n. neuropraxia, 6 radiolucencies, 
7 GT nonunion, 7 GT malunions 
Sebastia-Forcada E. et al. (165) 30 13.3   2 
 
2 
One humerus shaft fracture, one acromial 
fracture 
Obert L. et al. (166) 73 37.8 1  2 3 8 
Three brachial plexus  paralyses, one humeral 
fracture, two stiffnesses, four ossifications, one 
malunion GT 
Youn S. M et al. (167) 20 10     2 Two cases at risk of loosening 
Sebastiá-Forcada E. et al. (168) 31 6.5 1 1    
 
Cuff D.J. et al. (172) 24 8 1  
 
1 6 
Four tuberosity resorptions, one apical 
pneumothorax, one periprosthetic fracture, and 
one ulnar paresthesia 
Klein M. et al. (181) 20 15  2 1   
 
Total 375 
Aver. ± SD 
12.8 ± 9.3 
3 5 7 9 41 
 
GT: greater tuberosity
3.2 Retrospective study  
One hundred and five patients with PHF who underwent operative treatment from March 2017 
until June 2018 were screened. Out of these identified and screened case files, ten cases were 
excluded from the study for not meeting the full inclusion criteria either because the PHF was 
associated with shaft fracture extension, or the data was not sufficient to obtain a complete case 
assessment. Subsequently, out of the remaining 95 cases, seven were further excluded for receiving 
a surgical procedure other than arthroplasty or PHILOS (such as intramedullary nail (4), minimally 
invasive fixations (2), and fixation with a plate other than PHILOS (1). These seven cases receiving 
other treatment for PHF than PHILOS and arthroplasty were excluded from the analysis since their 
small number warranted them unsuitable as comparators. Therefore, a total of 17 patients were 
excluded from the study, leaving a study cohort of 88 PHF in 87 patients (Figure 8). In order to 
examine the representativeness of the selected sample, the distribution of gender, age, and 











Figure 9: The retrospective medical record review study flowchart 
Eighty-seven subjects met the inclusion criteria for this study and had complete clinical and 
records, including a follow-up period of at least six months, of whom 22 (18 females and 4 males) 
were treated with arthroplasty and 65 (44 females and 21 males) with PHILOS. The study 
population had an expectedly higher proportion of females (70.4%). The average patient age was 
72.9 years, 74.1 for patients who received arthroplasty and 72.5 for those who received the 
PHILOS plate. Table 2 presents a summary of the demographic and clinical characteristics of the 
study patients. In 83 patients, the cause of the fracture was due to a fall of low energy impact. In 
88 fractures in 87 eligible 
patients who receive 
arthroplasty or PHILOS were 
included in the final analysis 
 
10 patients were excluded due to  
 shaft fracture extension  
 insufficient data 
7 patients were excluded due to 
surgical procedures other than 
PHILOS or arthroplasty  
95 surgically treated PHF 
105 surgically treated PHF 
patients were screened 
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three cases, the fractures resulted from a polytraumatic event, and in two patients, the cause of 
fracture was not specified. According to Neer’s classification system, one fracture was classified 
as 1-part (1.1%), six fractures as 2-part (6.8 %), 44 fractures as 3-part (50%), and 37 fractures 
(42%) as 4-part fractures.  
Table 7: Demographic and clinical characteristics of the study patients 
Characteristics PHILOS group Arthroplasty group Total 
Number of PHF 66 (75%) 22 (25%) 88 (100%) 
Age (years) 
Min (years) 60 66 60 
Max (years) 93 85 93 
Mean±SD 72.5±5.1 74.1±7.9 72.9±7.33 
Number of fractures 
per gender (n/%) 
Female 44 (67.7%) 18 (81.8%) 62 (71.3%) 
Male 21 (32.3%) 4 (18.2%) 25 (28.7%) 
Hospital stay (days) 
Min (days) 3 4 3 
Max (days) 43 38 43 
Mean±SD 10±7.95 11±7.32 10.34±7.78 
3.2.1 Treatment approach and fracture classification 
Twenty-two patients (about 25%) with PHF underwent hemiarthroplasty or RSA, while the 
majority of study patients (about 75%) were treated with PHILOS fixation. It should be mentioned 
that all arthroplasty prostheses used in this study, were reversed shoulder arthroplasty except for 
only three hemi shoulder arthroplasty prosthesis cases, which used in 4-part fracture management. 
The complexity of PHF increases in patients with more displaced fracture fragments (16). The 3-
part fractures accounted for the largest group (n = 44; 50%), and 37 fractures (42%) were  4-part 
fractures. The most common treatment for 3-part fractures was the PHILOS (n = 43, 97.7%), while 
more cases with 4-part fractures were treated with arthroplasty (n=21, 56.7%), compared to ORIF 
(n = 16; 43.3%; Table 3). 
Table 8: Treatment approach (arthroplasty vs. PHILOS) and fracture classification 
Classification 
Treatment 
Total Arthroplasty, no. and 
percentage 























4-part 21 16 37 
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3.2.2 Overall complication rates    
Assessing the complication rate in PHFs treated with one of the two surgical approaches, either 
arthroplasty or PHILOS, was one of the main aims of this study. For the analysis, complications 
were defined as any adverse events directly related to the performed surgical procedure (64). Dindo 
et al. (151) classify the surgical complication into four main categories according to the treatment 
needed to manage these complications, where Type 1 is a minor event deviation requiring no 
surgical intervention, while Type 2 and higher are considered major and need active management 
and/or further surgical intervention (151). The complications included in this study  were all of 
Grade 2 or higher according to the surgical complication classification described by Dindo et al. 
(151).  
All available radiographs and medical records were evaluated to determine the type of 
complication in each case. Overall, complications were seen in 24 cases (27.3%) of the total study 
patients, of which 19 patients underwent PHILOS fixation, and five underwent arthroplasty. The 
complication rates were higher in the PHILOS group, comprising 28.7% (19 of 66) compared to 
22.7% (5 of 22) in the arthroplasty group (Table 4).  
Table 9: Overall complication rates according to surgical technique 
Treatment 

























3.2.3 Complication frequencies in each fracture type 
A careful analysis of the radiographs and the medical records of each patient was performed in 
order to identify the complications that had occurred within each fracture type (1-part, 2-part, 3-
part, and 4-part). The majority of postoperative complications were reported in 4-part fractures, 





Table 10: Complication frequencies in each fracture type 
Classification 







































A logistic regression analysis was then conducted to investigate the correlation between the 
complication rates and the fracture type or the surgical approach (both PHILOS fixation and 
arthroplasty). The hypothesis was that the surgical approach performed, as well as the type of 
fracture, influenced the rate of complications. The analysis showed that osteosynthesis (regardless 
of the fracture classification) had odds of complications 5.4 times the odds of complications in 
shoulder arthroplasty (OR 5.45, 95% CI: 1.32, 22.41). This difference was statistically significant 
(P-value, 0.019). Additionally, the analysis showed that 4-part fractures had odds of complications 
7.4 times the odds of the complications in 3-part fractures (regardless of the treatment approach) 
(OR 7.42, 95% CI: 2.10, 26.20). This difference was statistically significant (with P-value 0.002). 




Log likelihood = -42.811666 
Number of obs 81 
LR chi 2 (2) 11.03 
Prob > chi 2 0.0040 
Pseudo R2 0.1141 
Complication Odds Ratio Std. Err. z P > ǀzǀ [95% Conf. Interval] 
PHILOS 5.447749 3.931353 2.35 0.019 1.324189 22.41219 
4-part  7.415561 4.776572 3.11 0.002 2.098269 26.20758 
_cons .0416994 .0340794 -3.89 0.000 .0084038 .2069117 
Note: _cons estimates baseline odds. 
 
3.2.4 Complication frequencies in each fracture type and surgical approach 
Postoperative complications were then distributed according to the surgical treatment performed 
and the type of fracture for a better understanding of the relationship between these different 
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variables. Fifty-eight percent of patients (11 of 19) with 4-part fractures vs. 36.8% of patients (7 
of 19) with 3-part fractures treated with PHILOS fixation suffered from postoperative 
complications. In the arthroplasty group, four out of all five patients recorded with complications 
suffered from 4-part fractures (Table 7).  
Table 12: Complication frequencies in each fracture type and surgical approach 
  1-part fracture  2-part fracture  3-part fracture  4-part fracture  
          Complication             
Treatment 
yes no yes no yes no yes no 
PHILOS (n= 66) - 1 1 5 7 36 11 5 
Arthroplasty 
(n=22) 
- - - - 1 0 4 17 
Total  1 1 5 8 36 15 22 
A logistic regression analysis was then conducted to investigate the correlation between the 
fracture type and complication rates for PHILOS fixation. The hypothesis was that in PHILOS 
fixation, the type of fracture could influence the rate of complications. In this analysis, the 
correlation was examined between the rate of complication and 4-part fracture classification (in 
comparison to 3-part fracture) for patients who underwent PHILOS plate. This analysis focused 
only on the PHILOS group due to the higher number of patients and the rate of complications. The 
model showed that 4-part fractures, when treated with PHILOS fixation, had odds of complications 
11 times the odds of complications in 3-part fractures (OR 11.31, 95% CI: 2.99, 42.85). The 
difference was statistically significant (P<0.0001). 






Log likelihood = -29.040934 
Number of obs 59 
LR chi 2 (1) 14.50 
Prob > chi 2 0.0001 
Pseudo R2 0.1998 
Complication Odds Ratio Std. Err. z P > ǀzǀ [95% Conf. Interval] 
4-part  11.31429 7.68659 3.57 0.000 2.987763 42.84579 
_cons .1944444 .0803211 -3.96 0.000 .0865329 .4369278 




The next logistic regression analysis (Table 9) examined the correlation between the rate of 
complication and the PHILOS fixation (in comparison to arthroplasty) for patients who suffered 
from 4-part fractures. The model showed that patients with 4-part fractures, when undergoing 
PHILOS fixation, had nine times the odds of suffering from a complication than when undergoing 
arthroplasty. (OR 9.35, 95% CI: 2.05, 42.66) The difference was statistically significant (P<0.004). 
Table 14: Logistic regression model for the effect of surgical technique on complication rate in 4-part fracture  




Log likelihood = -20.162549 
Number of obs 37 
LR chi 2 (1) 9.64 
Prob > chi 2 0.0019 
Pseudo R2 0.1929 
Complication Odds Ratio Std. Err. z P > ǀzǀ [95% Conf. Interval] 
PHILOS 9.35 7.240865 2.89 0.004 2.049371 42.6582 
_cons .2352941 .1307574 -2.60 0.009 .0791739 .6992619 
Note: _cons estimates baseline odds. 
 
These results confirmed that the treatment modality, as well as the type of fracture, influenced the 
rate of complications. In patients with Type IV fractures, PHILOS fixation was associated with 
higher complication rates.  
3.2.5 Complication patterns and revision surgeries 
The primary cause of postoperative complications in the PHILOS group was the loss of reduction, 
which amounted to 33.3% (9 of 27) of all reported complications. A single patient could have more 
than one complication reported. Loss of reduction was the most prevalent complication in the 
PHILOS group (n=9), followed by infection (n=4). Complications in the arthroplasty group, with 
the majority being infections, were mainly observed in 4-part fractures. Overall, the PHILOS 
group showed a higher number of complications (n=22) compared to the arthroplasty group (n=5). 
The complicated arthroplasty cases included two RSA cases and three hemiarthroplasty cases. All 
three of these cases of hemiarthroplasty were used to treat 4-part PHF and ended with 
complications and revised later on with total shoulder arthroplasty. This means that, between the 
4-part PHF treated with arthroplasty, there were four complicated cases; three of them were treated 
with hemiarthroplasty, and only one case was treated with RSA. The complications seen in 





Table 15: Complication patterns for each surgical approach 
Type of complications 
PHILOS group Arthroplasty group Total 
2-part 3-part 4-part 3-part 4-part  
Loss of reduction 1 2 6 NA NA 9 
Infection - 2 2 1 2 7 
Screw cut-out - 3 1 NA NA 4 
Pseudo-arthrosis - - 1 NA NA 1 
Pseudo-paralysis - - 1 - - 1 
Dislocation NA NA NA - 1 1 
Primary long screw 1 - - NA NA 1 
Instability NA NA NA - 1 1 
Avascular necrosis - 1 - NA NA 1 
Nonunion - - 1 NA NA 1 
Total 2 8 12 1 4 27 
NA, Non-applicable  
 
Among all study patients, 13 (14.7%) underwent at least one revision surgery in order to manage 
the postoperative complications. The PHILOS revision cases were loss of reduction in four cases, 
nonunion in two, infection in one, and primary long screw in one case. Arthroplasty revision cases 
included infection in three, instability/dislocation in two cases. The overall (3- and 4-part fracture) 
revision surgery rate was higher after arthroplasty (22.7%) than after the PHILOS plate fixation 
(12.1%) surgeries. In 4-part fractures the number of revision surgeries was higher in the PHILOS 
treated group (5 of 16 patients) compared with the arthroplasty group (4 of 21 patients).  




Number of revision surgeries 
Total 
2-part 3-part  4-part 
PHILOS 66 1 2 5 8 (12.1%) 
Arthroplasty 22  1 4 5 (22.7%) 
Total 88 1 3 9 13 (14.7%) 
 
To further illustrate the different types of reported postoperative complications and some of the 
management approaches, three cases were selected from the study patients and described in more 
detail. The first case (Figure 9) was a patient who underwent PHILOS fixation and suffered from 
loss of reduction one month following the surgery. The loss of reduction was, in this case, the 
displacement of the greater tuberosity from the anatomical position. This patient underwent 
revision surgery.  
55 
 
                                                    
Figure 10: Loss of reduction in PHILOS plate fixation.   
(a) and (b) postoperative, (c) one month later shows loss of reduction of the greater tuberosity (white arrow).   
 
The second case was also a patient who underwent PHILOS plate fixation. Similar to the first case, 
the patient suffered from a loss of reduction two months after surgery (Figure 10 D). In addition, 
it could also be observed that the patient had multiple screws cut-out through the subchondral bone 
lamella of the humeral head (Figure 10 C & E). The X-ray series of this patient showed multiple 
postoperative complications (loss of reduction and cut-out).  
  
 
   
Figure 11: Loss of reduction and screws cut-out in PHILOS plate fixation.  
(A) after fracture (B) after fixation. (C), (D) and (E) after two months of follow-up 
a) Post-operative b) Post-operative c) One month later 




The third patient underwent hemiarthroplasty and suffered from infection (Figure 11). This case 
was treated with a two-stage exchange procedure. In the first stage (Figure 11 B), removal of the 
infected prosthesis and bone cement was performed, followed by the debridement of the wound to 
remove any infected or dead tissue. Then a cement spacer impregnated with antibiotics was 
inserted, and the patient was given a course of antibiotics to control and treat the infection. In the 
second stage (Figure 11 C), a new prosthesis was inserted (RSA).  
 
   
Figure 12: Infected shoulder hemiarthroplasty.  
(X-ray A) Hemiarthroplasty, axial view, (X-ray B) spacer after infection, (X-ray C) revised by RSA after treatment 
of infection. 
 
Clinical relevance of the retrospective study sample:  
As indicated in table 1, the PHILOS's overall complication rate as reported in selected studies 
ranged between 9.7% and 57%, with the average complication rate being 27.9% and a standard 
deviation of 14.5%. We relied on these calculations to test the clinical relevance of our sample 
size. We then calculated the confidence interval of the included sample using the following 
equation (185). 
𝐶𝐼 = 𝑃 ± 𝑑 




Where d is the margin of error, Z is the Z score for a level of confidence, P population proportion, 
and n is the sample size  (186). The confidence level is 95%, the proportion is 27.9%, and the 
sample size is 66. This has resulted in a margin of error of 10.82%, which can be interpreted as a 
95% chance that the real complication rate is within ±10.82% of the measured complication rate. 
This margin of error (10.82%) was more conservative than the wide range of complication rates 
A B C 
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observed in the literature (31.3 ± 15.2). In other words, the study sample of 66 can be considered 
appropriate to provide clinically relevant results.  
In this calculation, we relied only on cases that received the PHILOS since reversed shoulder 
arthroplasty overcame the healing problem from the start by replacing the fractured head with the 
prosthesis. Thus, the outcome of the arthroplasty treated cases was not the primary focus of this 
retrospective study.  Therefore, we provided a descriptive analysis of these cases. However, the 
finding that three out of the four arthroplasty cases with complications were Hemiarthroplasty is 
noteworthy to our mind. Unlike the reverse shoulder arthroplasty, tuberosity healing in 
Hemiarthroplasty is of great importance for a satisfactory clinical outcome. Tuberosity nonunion 
or malunion could be considered the most common cause of Hemiarthroplasty failure (29, 182, 
187, 188). Delayed healing of the greater tuberosity leads to malposition and migration of the 
tuberosity, which may cause prosthesis subluxation (183). Moreover, tuberosity migration and 
malposition decrease the lever arm of shoulder abductors and change the tension of the rotator cuff 
complex. This significantly increases the needed torque for shoulder mobilization, which 
considerably affects the rotator cuff function and shoulder range of motion (189). Therefore, 
hemiarthroplasty patients could be considered as a potential future targeted population for healing 
enhancement therapy. 
3.3 Devising a clinical testing strategy  
The retrospective medical record analysis enabled us to determine the baseline complication rate 
and the rate of revision surgeries after PHF surgeries. Moreover, it helped us to identify the group 
of patients with the least favorable outcome after PHF surgery. Patients (> 60y) who underwent 
angle stable plate fixation, particularly with 4-part fractures, were associated with higher 
complication rates (figure 12). Within the ORIF group, as shown above, 3-part fractures were also 
associated with a significant complication rate. The most frequent complication in PHILOS groups 
(3-part and 4-part fractures) was related to compromise bone healing. Therefore, improving bone 
healing in these PHILOS treated group would be of great advantage. Hence, both cohorts, patients 
with 3- and 4-part fractures were identified as an optimal target group for an intervention trial.  
The second part of this study focused on translating a novel, potentially beneficial treatment 
(immunomodulatory therapy) from the preclinical stage into the clinic by designing a clinical trial 
to investigate the potentially positive effect of immunomodulatory therapy on bone healing in PHF 
patients. In this context, a clinical trial was designed to check the safety as well as the efficacy of 
a local use of Iloprost, an analogue of prostacyclin PGI2, as an immune-modulatory therapy to 
enhance bone healing. The expected effect of local Iloprost application at the fracture site is the 
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enhancement of the local fracture milieu and the control of the early inflammatory phase. In order 
to investigate this approach in the identified patient population within the parameters of a clinical 
trial, several points had to be addressed adequately, such as the determination of dosage and dose 
regimen, choice of clinically representative endpoints, and establishing a benefit-risk assessment 
profile for the investigational product. Finally, the study entailed creating and submitting 
documents needed for clinical trial approval to the relevant authorities (please see sections 1.7.1 
and 1.7.2). 
 
Figure 13: Number of complications in each fracture type and surgical approach 
3.3.1 The proposed study design 
The Iloprost study is a Phase I/IIa, prospective, mono-center, randomized, open-labeled, controlled 
study investigating the safety and clinical efficacy of Iloprost local application at the proximal 
humeral fracture site.  
Study hypothesis: The local administration of Iloprost as an immunomodulatory agent at the 
fracture site is safe and could enhance bone healing in elderly patients with PHF. 
Patients who fulfill the inclusion and exclusion criteria will be eligible to enter the study. Patients 
will be randomized on a 1:1:1 basis to one of the three arms (two treatment arms and one control 
arm). 
The first intervention group will receive an open reduction and internal fixation (ORIF) with an 
angular stable plate (PHILOS) + Iloprost treatment. Patients will locally receive a dose of 0.125 
ng/kg/min of Iloprost over 24 hours via a catheter and an electronic pump system. The catheter 
will be inserted during the surgical procedure. The infusion of Iloprost will start 24hrs post-
operatively, and the dose will be delivered over 24h. 
The second intervention group will also receive ORIF with an angular stable plate (PHILOS) + 





























via a catheter and an electronic pump system. The infusion will start 24hrs post-operatively, and 
the dose will be delivered over 24h. 
Control intervention: Patients will receive only ORIF with the PHILOS.  
Follow-up per patient: 52 weeks, of which 26 weeks include active study participation. At the 
study end, a telephone call with the patients to ensure safety assessment. 
Duration of intervention per patient: local Iloprost application for 24 hours starting 24 ±2 hours 
after surgery 
 
Figure 14: Flow diagram of the study design 
 
3.3.2 Determining the dosage of the investigational drug  
The choice and calculation of the dose used in this clinical trial relied on a multi-faceted strategy 
that took into consideration the benefit-risk profile of the drug. In particular, factors such as bone 
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vascularity, rate of infusion, and previous data from the animal model were taken into 
consideration as follows:  
a) Given the high vascularity of bone, applying Iloprost locally to the site of fractures is expected 
to reach the vascular system. Applying Iloprost in this fashion is, to a great extent, similar to its 
market use via the intravenous route. To ensure patients' safety, the same recommended IV dose 
used in pulmonary hypertension was opted for the local infusion. Nevertheless, the drug is not 
expected to reach the same blood concentrations as in the case of IV infusion due to the slower 
infusion rate (see under b). 
b) Iloprost has narrow therapeutic indices and a short half-life of 30 min. and is infused IV over 
six hours in its standard indication (190). Since Iloprost is known to show a reduction in tolerability 
and increase of side effects at higher infusion rates, the infusion period was extended from 6 to 24 
hours to lower the possibility of any systematic toxicity and in order to increase the exposure time 
of the fracture to the drug. In this way the infusion rate (mL/hour) was reduced four-fold.  
c) There is a direct correlation between body weight and bone mineral density (BMD) (191, 192). 
Bodyweight and body mass index (BMI) act as modifiable factors in the determination of bone 
mineral density (193). For instance, every unit increase in BMI was associated with a rise of 0.008 
g/cm2 in L1-L4 BMD, 0.017 g/cm2 in femur neck BMD, and 0.018 g/cm2 in total hip BMD (194). 
Therefore, applying Iloprost according to body weight is expected to tailor the efficacy profile of 
the drug to each patient individually, an approach that would yield the best clinical outcome while 
mitigating any potential risks.  
d) Finally, the dose was calculated to a greater extent based on the animal study that was previously 
performed by the research group in the (BCRT) (Box 1). The bone formation was analyzed in a 
drill hole model for four different groups in a sheep model: empty, gelatin only, gelatin with 
Iloprost, and bone graft group. The empty control group and the gelatin group were used as 
negative controls. Even though the efficacy of Iloprost using this dose was not found to be superior 
to controls because Iloprost was immediately given following bone injury and not as in the 
proposed trial after 24 hours, this dose did not show any toxicity and was well tolerated. Therefore, 
given all of these factors (a) to (d), it was evident that the weight adapted I.V. dose of Iloprost will 






Box 1: Dose calculation for the planned study 
The human dose was calculated based on the Iloprost dose investigated in a sheep model after 
calculating the human equivalent dose as follows:  Human Equivalent Dose (HED) = animal 
dose (mg/kg) × [animal weight (kg) ÷ human weight (kg)]0.33 (195) 
• The Iloprost dose investigated in sheep was 20 µg. The average sheep weight in 
this experiment was 80 kg, then the dose/kg is 20 µg /80kg = 0,25µg/kg   
• Using the average human weight of 70 kg, HED= 0.25 *(80/70)0,33  = 0.26 µg/kg  
The Iloprost dose will exemplarily be 0,26*70=18,28 µg in a patient with 70 kg body weight. 
This dose falls within the established IV dose range for the currently marketed indication 
(from 0.5 ng/kg/min to 2 ng/kg/min bodyweight over 6 hours IV drip, which equals to 12.6- 
50.4 µg for an average 70 kg patient). Therefore, relying on the established physiological 
dose of Iloprost was seen as the most reliable strategy.  
 
Patients will be randomized into either one of three groups. All three groups will receive an open 
reduction and fixation of their PHF with the PHILOS (three arms). The first treatment arm will 
start treatment with Iloprost 24 hrs post-operatively; patients will receive a single dose of 0.125 
ng/kg/min of Iloprost infused over 24 hours. The second treatment arm will start treatment with 
Iloprost 24hrs post-operatively; patients will receive a single dose of 0.25 ng/kg/min of Iloprost 
infused over 24 hours. Patients randomized to the third treatment arm will only receive the 
PHILOS plate, and their outcome will be compared to the other two treatment arms. 
 
3.3.3 Selecting clinically representative endpoints and relevant controls 
The planned study is a Phase I/IIa, prospective, mono-center, randomized, open-labeled, controlled 
study investigating the safety and clinical efficacy of local Iloprost application at the proximal 
humerus fracture site. The primary endpoint of the planned trail was determined as safety, through 
the identification of any noxious response or toxicity that has a causal relationship to the treatment. 
Toxicity shall be graded according to the National Cancer Institute Common Terminology Criteria 
for Adverse Events (NCI-CTCAE) (196).  
Clinical endpoint 
The degree of preservation of the summation of the tip-apex distance (TAD) for the humeral head 
screws of the PHILOS at the 12 weeks postoperative follow-up visit compared to the immediately 




To investigate the therapeutic effect of Iloprost on the study participants, a radiological endpoint, 
the tip apex distance (TAD) measurement, was determined, which is considered to be directly 
related to the quality of fracture healing. TAD refers to the distance between the tip of the PHILOS 
screws and the subchondral outer cortex of the humeral head (fig. 14), which will be measured at 
12 weeks postoperatively and compared to the baseline measurements after surgery. This endpoint 
is an indicator of the progress of fracture healing and the probability of potential complications. 
Thus, the endpoint reflects both the safety and efficacy of the investigational treatment (197).  
 
Figure 15: Tip Apex Distance  
(TAP) is the distance between the tip of the screw and the humeral cortex (red double arrow) (197) 
The degree of TAD preservation shall be classified into one of five arbitrary ranks based on the 
mean of the TADs of all screws: 
 Grade 1: 76%-100% preservation of the original distance (representing the best possible 
result) 
 Grade 2: 51%-75% preservation of the original distance 
 Grade 3: 26%-50% preservation of the original distance 
 Grade 4: 0%-25% preservation of the original distance 
Grade 5: If the patient shows signs of screw protrusion (cut out) through the subchondral bone, 





By assessing the following secondary endpoints, further clinical parameters of treatment efficacy 
could be evaluated: 
 Rate of humeral head necrosis 
 Change in the humeral head shaft angle (198) 
 Pain assessment using the Visual Analogue Scale (VAS) (199) 
 Quality of life by applying the questionnaire EuroQol-5 Dimension (EQ-5D) (200) 
 Constant-Murley Score (CMS) (201) 
 Disabilities of the Arm, Shoulder and Hand score (DASH) (202) 
3.3.4 Identifying inclusion and exclusion criteria to assess the suitability of the study 
population 
Patient selection was decided based on stringent criteria that are of critical importance both to 
protect the patient's rights and to assure valid data on outcomes. Only participants over 60 years 
of age were included in the study. The complete list of inclusion and exclusion criteria for the 
planned study is as follows: 
a) Inclusion criteria: Patients are eligible to participate in the study if they fulfill the 
following inclusion criteria:  
 Signed written informed consent 
 Adult male or female patients 60 to 80 years of age at the time of screening 
 Scheduled ORIF with PHILOS (three-hole PHILOS) for proximal humerus fracture Type 
3 or 4 according to Neer classification 
 Patient with American Society of Anesthesiologists ASA score of ≤ 2 
 Single, low energy fracture 
 Absence of neurovascular complications at the time of trauma 
 Surgery was performed within the first 96 hours of injury 
 
b) Exclusion criteria: Patients are not eligible to participate in this study and cannot be 
enrolled in the study if one or more of the following exclusion criteria are met:  
 Subjects unable to freely give their informed consent (e.g., individuals under legal 
guardianship) 
 Immunosuppression due to illness or medication.  
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 Subject with malignancy and undergoing treatment including chemotherapy, radiotherapy 
or immunotherapy 
 Known allergies to Iloprost 
 Conditions where the effects of Iloprost on platelets might increase the risk of hemorrhage 
(e.g. active peptic ulcers or intracranial hemorrhage) 
 patients with a history of cerebral circulatory disorders  
 patients with any symptomatic or treatable heart disease (including stenting), hypertension 
treated with a β-receptor blocker, calcium agonists, vasodilator or ACE inhibitor at more 
than moderate doses  
 Severe coronary heart disease or unstable angina; myocardial infarction within the last six 
months; decompensated cardiac failure if not under close medical supervision; severe 
arrhythmias; suspected pulmonary congestion; cerebrovascular events (e.g., transient 
ischaemic attack, stroke) within the last three months 
 Acute or chronic congestive heart failure (NYHA II-IV) 
 Pulmonary hypertension due to venous occlusive disease 
 Congenital or acquired valvular defects with clinically relevant myocardial function 
disorders not related to pulmonary hypertension 
 A patient currently enrolled in or has not yet completed at least (a period equal to five times  
the half-life time of the drug used in the previous trial) since ending other investigational 
device or drug trial(s) 
 Patients dependent on sponsor, investigator or study site 
 History of previous proximal humerus surgery on the same side 
 History of proximal humerus deformity on the same side 
 Pathological or open fracture 
 Polytrauma patient 
 Any form of substance abuse, psychiatric disorder, or other condition that, in the opinion 
of the Investigator, may invalidate communication with the Investigator and/or designated 
study personnel 
 Patients committed to an institution by virtue of an order issued by either the judicial or 
the administrative authorities 
3.3.5 Identifying potential harms (Adverse event (AE) and serious AE (SAE)) 
The known adverse drug reactions (for systemic use) which were reported in the post-marketing 
surveillance of Iloprost are listed in Table 12 (190), however, due to local infiltration of the Iloprost 
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at a slower rate than the IV dose rate, the adverse reactions during the planned trial are expected 
to be lower than the side effects of the systemic use. With this slow rate of local infusion, only 
mild side effects like dizziness or headache for a short duration can be expected. In such situations, 
the patient will receive the adequate management, and if the condition does not improve, the 
infusion of the drug will be stopped, and the patient will continue to receive the required care. 
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* Life-threatening and/or fatal cases have been reported 
 
3.3.6 Establishing clinical monitoring measures during the infusion of Iloprost 
Several clinical monitoring measures were devised and established for the planned study to 
ensure the safety of the study participants.  
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a) Infusion rate: The planned infusion rate of Iloprost in the clinical trial is four times slower than 
the data-sheet (190) recommended dose for pulmonary hypertension patients. This slow rate of 
local infusion is expected to decrease the expected side effects of Iloprost significantly. 
Moreover, the enrolled patients will be monitored during the time of the infusion, and in the case 
of occurrence of any serious side effects, the infusion will be discontinued. 
b) Baseline patient characteristics and additional precautions: The Iloprost data-sheet requires 
the reduction of the administered dose in patients with renal or hepatic impairment. These patients 
are excluded from the planned study. Additionally, all contraindications stated in the Iloprost data 
sheet are included in the exclusion criteria of the planned study. Furthermore, the following 
precautions will be taken during patient monitoring following infusion: 
a. In patients with low blood pressure, care will be taken to avoid further hypotension. Similar 
to what is recommended for Iloprost, in the planned study, the drug will not be administered 
in patients with systolic arterial hypotension less than 85 mmHg. Thereafter, blood pressure 
and heart rate will be measured 15 min. and 30 min. after the beginning of the infusion, 
then every two hours during the first six hours, and finally every six hours until the end of 
the infusion (48 hrs after the surgical procedure). 
b. Care will be taken to avoid any contamination arising from the procedures necessary for 
the administration of Iloprost. 
c. Oral ingestion and contact with mucous membranes will be avoided. On contact with the 
skin, Iloprost may evoke erythema, which could be long-lasting but painless. Suitable 
precautions will be taken to avoid Iloprost contact with the skin. In the event of Iloprost 
contact, the affected area will be washed immediately with water or saline. 
d. Although highly unlikely, in the event of myocardial ischemia provoked by an overdose of 
Iloprost, the administration of 125 mg aminophylline IV has been shown to be an effective 
countermeasure. Iloprost administration will be interrupted, and close monitoring of the 
affected patient together with symptomatic measures will be carried out. 
c) Oversight during administration: The investigational drug will be used under strict control at 
the Center for Musculoskeletal Surgery of the Charité, which is equipped with the appropriate 




3.3.7 Establishing an overall benefit-risk assessment of the investigational drug 
3.3.7.1 Risk assessment 
Iloprost has been proven to exhibit an acceptable safety profile and has obtained marketing 
authorization for pulmonary hypertension in the European market under the marketing 
authorization number EMEA/H/C/000474 in 2003. Iloprost is also FDA approved and routinely 
used in clinical practice for pulmonary hypertension. Moreover, Iloprost has also been used for 
Buerger disease (thromboangitis obliterans), scleroderma, and ischemia (130). Furthermore, 
Iloprost has previously been successfully used off-label to treat  bone marrow edema in early cases 
of osteonecrosis (132–135, 137). Iloprost is administered via intravenous infusion or inhalation. 
However, in this study, Iloprost shall be administered via the local application at the fracture site, 
which is considered a new method of Iloprost application for a new indication. The potential risks 
that could result from this new application method can be attributed to the following sources: 
 Local administration of Iloprost 
 Potential systemic adverse events that would stem from the drug reaching the systemic 
circulation 
 Catheter insertion for delivery of Iloprost 
a) Local administration of Iloprost 
Observations that support the local tolerance of Iloprost were also collected from the in 
vivo experiments, and experiments gathered from the literature. Neither the mouse (100) 
nor the sheep model (unpublished data) experiments performed by the research group in 
the (BCRT) revealed any local toxicity, and no negative effect on the cellular composition 
at and around the fracture gap was observed. Moreover, other research groups have 
investigated the local application of Iloprost in other tissues. For instance, researchers at 
Boston University School of Medicine investigated the use of PGI2 analogs such as 
Iloprost and carbaprostacyclin (cPGI) in the murine corneal model of angiogenesis (203). 
The corneal tissue is commonly used to examine the potential angiogenic impact of an 
experimental drug. The experiment revealed that Iloprost and cPGI are able to induce 
angiogenesis in the murine model, and most importantly, they did not report any signs of 
local toxicity (203, 204). 
The safety and tolerability of local treatment with Iloprost were investigated in patients 
with Peyronie's disease (progressive fibromatosis characterized by inflammatory plaques 
on the dorsolateral aspect of the penis, which can cause both pain on erection and penile 
curvature) in Phase I clinical trial (205). Researchers performed intralesional injections of 
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an Iloprost dose of 200 ng in 1 mL normal saline for five weeks into the penile tissue to 
explore the drug’s ability to suppress the production of connective tissue growth factor in 
fibroblasts, for the treatment of Peyronie's disease. All patients tolerated an Iloprost dose 
of 200 ng well; 19 patients reached a 300 ng dose, and 14 tolerated a 400 ng dose without 
showing serious side effects.  Only mild side effects (burning or pain) at the site of injection 
were recorded during the treatment. Given the high vascularity of the penile tissue, it is 
expected that the majority, if not the entire amount of directly injected Iloprost, reaches the 
systematic circulation of patients. Overall, the local tolerance of Iloprost has been positive, 
and the drug did not show any significant signs for concern in either preclinical or clinical 
settings.  
 
b) Potential systemic adverse events that would stem from the drug reaching the 
systemic circulation 
Possible adverse events that could arise from Iloprost reaching the systemic circulation are 
listed in Table 12. However, the occurrence of these events is most unlikely, and in order 
to minimize potential toxicity that could occur from Iloprost reaching the systemic 
circulation, the following measures have been defined to counter the respective risk as also 
given above: 
1) Iloprost infusion rates will be four times slower than the rate of the recommended IV 
infusion dose for pulmonary hypertension patients. This aims to lower the possibility of 
any systematic toxicity and increase the exposure time of the fracture to the drug.  
2) The exclusion criteria of the trial included all contraindications and precautions of the 
intravenous use of Iloprost. 
3) All study patients will be monitored during and after the infusion of Iloprost for any signs 
or symptoms of adverse reactions, and appropriate symptomatic treatment will be initiated. 
 
c) Catheter insertion for delivery of Iloprost  
It is planned to infuse Iloprost locally to the fracture site through a catheter (InfiltraLong 420,  
PAJUNK® GmbH, Geisingen / Germany). InfiltraLong 420 is CE certified (no. 51268-16-02) as 
a pre-assembled kit for wound infiltration/ infiltration analgesia. All precautions will be taken to 
reduce any potential risks that can be associated with the procedure itself, such as the risk of 
contamination. The catheter insertion will be performed during the surgical procedure in the 
operating theatre under strictly aseptic conditions and according to the standard protocol for 
surgical catheter insertion. 
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 The rationale for using the InfiltraLong Catheter 
After fracture fixation with the PHILOS plate, the catheter will be inserted at the end of the surgical 
procedure just before skin closure. The catheter will be inserted to reach the closest point at the 
fracture site, enabling the diffusion of Iloprost to the fracture hematoma. The technique of 
continuous wound infiltration is widely used postoperatively as a postoperative analgesic 
technique to decrease the need for postoperative systemic analgesia. This technique includes 
administering local analgesics directly into the surgical wound with a continuous infusion rate 
through the insertion of a multi holed catheter to the surgical site at the end of the surgical 
procedure (206). Local wound infiltration of an anesthetic has been widely used in orthopedic 
surgery effectively, which has been proved to decrease the postoperative systemic analgesia after 
lumbar disc surgery (207). Furthermore, this technique is considered to be safe and effective in 
pain management after lumbar laminectomy (208). The local infiltration of analgesia could be 
considered as a part of the multi analgesic technique for hip and knee replacement surgeries (209, 
210).  This has been further revised in a systematic review showed that the analgesic local 
infiltration method is an effective analgesic method in total hip replacement (211). Furthermore, 
local wound analgesia infiltration has been advised after iliac crest bone grafts as an effective 
method of analgesia for the known prolonged donor site pain (212).  
Therefore, the usage of Iloprost locally through a catheter inserted into the fracture site during the 
surgical procedure is considered a feasible and straightforward method not only to deliver Iloprost 
to the fracture site but also to control its dose and infusion rate. 
 Precautions against catheter blockage  
The (InfiltraLong 420) catheter has a flexible helical coil to always keep its lumen open and ten 
openings in spiral arrangement with precisely chosen hole diameter along 25 mm at the tip to 
ensure a uniform and homogeneous distribution of the infused fluid along the catheter length (213). 
The infusion pump will be connected with the catheter in the operating room, and saline infusion 
of lowest rate (0.1ml/h with a total of 2.4 ml/ day) will start immediately in order to avoid blockage 
of the catheter before Iloprost infusion starts 24 hours after the procedure. Additionally, close 
monitoring of the patients will be carried out during the infusion of Iloprost to ensure the integrity 
of the catheter and the continuous delivery of the drug. 
3.3.7.2 Benefit assessment 
In recent years, the potential role of Iloprost as an immune-modulatory agent has been observed 
as promoting an anti-inflammatory and immunosuppressive effect (128, 129). Due to the strong 
correlation of the immune system and the skeletal system during bone regeneration, Iloprost could 
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represent a potential and promising agent to further bone fracture healing. Moreover, Iloprost helps 
to optimize the immune response by avoiding the prolonged and excessive pro-inflammatory 
reaction that could negatively influence musculoskeletal healing (109). Further investigation of 
the immune-modulatory effect of Iloprost in the context of bone regeneration has been conducted, 
where in vitro studies confirmed the postulated positive osteogenic effect (100). In a final proof of 
concept in vivo study, the positive impact of a local application of Iloprost into the fracture site 
during the early phase of bone healing was evidenced in a mouse osteotomy model (100).  
Moreover, in the context of bone injuries, Iloprost was previously successfully used off-label to 
treat bone marrow edema and avascular necrosis via its vasodilator effect and the enhancement of 
capillary microcirculation, as well as decreasing the oxygen-free radical production and preventing 
thrombocyte adhesion (131–133, 137, 138). 
The established efficacy from the in vitro and in vivo mouse models coupled with the safety and 
tolerability profile of the drug seen in the sheep model all together is seen as a strong body of 
evidence that justifies the need to investigate Iloprost in a target patient population as a next logical 
step. The local application of Iloprost into fracture sites would represent a new therapeutic 




Chapter 4 : Discussion 
The displaced proximal humeral fracture is one of the unsolved orthopedic problems, especially 
in elderly patients (214). There are no clear evidence-based guidelines for PHF treatment, which 
could explain the current conflicting opinions in the scientific community (20). The literature 
review, which was conducted in the frame of this thesis, confirmed the controversy around 
treatment options for PHF, which is not only about deciding between conservative or surgical 
treatment but also in determining the optimal surgical procedure for displaced PHF (17, 215). It 
has been reported that 70% of 3- and 4-part PHF occur in the patient age group above 60 years 
old, while most of these patients are advised to be treated surgically to ensure better outcomes 
(216), as conservative treatment options are no guarantee for a satisfying outcome (22–24). The 
following interpretations could be deduced from this literature review: 
1. No clear consensus on the surgical approach of choice for surgical fixation of PHF: The PHF 
is one of the three most common fractures in elderly patients, mainly after a simple fall (5–7). This 
number is expected to be tripled in the next three decades due to an aging population (10, 11). 
Finding the proper treatment for such patients is not easy despite the wide range of treatment 
varieties, partially due to the lack of specific treatment guidelines for PHF (17, 20). Therefore, a 
full assessment is necessary for each patient to find the best possible treatment approach. The 
assessment process should include multiple considerations, such as the patient's general condition 
and daily activity, in addition to the local evaluation of the fracture and bone quality (31, 49).  
2. Screw cut-out was the most common complication reported after PHF fixation surgery: 
Angular stable locking plates such as PHILOS have a potential advantage of preserving the 
anatomical alignment of the humeral head and save the joint integrity by optimizing the tension of 
the surrounding structures, which could provide favorable outcomes (88). However, PHILOS has 
a relatively high and heterogeneously reported complication rate varying from 7% (156) to 60% 
(177) with an average of 31.3 ± 15.2%. This high variability could be mainly due to the 
heterogeneity of the study population with different degree of fracture classifications, and finally, 
the comprehensibility of reporting the complication rate in each study.  
The literature review showed that screw cut out is the most common reported complication (81 
out of 207), followed by avascular necrosis of the humeral head (39 out of 207) and loss of 
reduction (24 out of 207). The cut-out was found in 81 cases out of 471 patients in 15 studies 
treated with PHILOS (Table 3), representing an average incidence rate of about 17%. Furthermore, 
loss of reduction and head collapse following avascular necrosis could lead to screw cut-out due 
to the high mechanical demand transferred mainly through the plate and screw and not through the 
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bone (88). Therefore, achieving rapid bone healing could help in earlier load transfer through bone 
and decrease bone cut-out incidences. Similar observations were seen for patients treated with an 
intramedullary nail where screw cut out was the most common complication (9 out of 33) (Table 
4).       
Hemiarthroplasty was used in 254 patients in eight studies (Table 5).  The most frequently found 
complication was represented by greater tuberosity healing problems such as loss of reduction with 
subsequent malunion or nonunion. Achieving proper tuberosity healing could significantly affect 
the patient outcome after Hemiarthroplasty. Tuberosity malunion and nonunion were previously 
defined as the most common reasons for hemiarthroplasty failure (29, 182, 187, 188). Therefore, 
achieving rapid healing could improve the functional outcome of such patients. Finally, Reversed 
shoulder arthroplasty (RSA) was used in 375 patients in ten studies (table 6). RSA showed the 
lowest complication rate, with an average of 12.8% ± 9.3%. RSA has the advantage over 
Hemiarthroplasty in preserving the patient's ability to abduct and elevate the affected arm even in 
the absence of tuberosity healing. However, nonunion of the tuberosities have been linked to 
severe complications such as instability, loosening, and even infection (67, 217). Moreover, 
Boileau P. et al. (218) showed that tuberosity healing in RSA could improve external rotation and 
active forward elevation and, subsequently, patient satisfaction (218).  
Additionally, the heterogeneity of clinical outcomes given in the literature makes it challenging to 
calculate a specific baseline complication rate for PHF. As such, the situation necessitated such 
retrospective analysis, focusing on patients treated at the Center for Musculoskeletal Surgery at 
the Charite University Hospital. The retrospective analysis described in this thesis aimed at 
identifying the patient group with the highest complication rate who underwent surgical treatment 
following PHF in patients aged 60 years or older. Finding the baseline complication rate of PHF 
after osteosynthesis is essential to highlight the healing problem in this particular age group as 
well as to determine the target population that could benefit from potential therapeutic approaches 
for bone healing improvement.  
 
Retrospective analysis of patients suffering from PHF 
 
Patients with 4-part fractures treated with ORIF showed a higher rate of complications 
In this study, 75% (66 out of 88) of PHF were treated with PHILOS plate fixation, while the 
remaining were treated with arthroplasty. This high percentage of cases treated with the PHILOS 
plate also reflected in the conclusion of Bell et al. (219) that there is a general tendency to treat 
more patients suffering from PHF with angle stable plate ORIF. This conclusion was based on 
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studying PHF treatment methods in 306 referral hospitals in the USA, comparing the current 
number of PHF fixation cases with the number five years earlier. The study showed an increase in 
the percentage of PHF fixation in the elderly by 29%, assuming that the incidence of PHF had not 
significantly changed over the five years of the study (219). This means that there is a real increase 
in the number of elderly patients being treated with surgical fixation. The increase in the PHF 
treated with surgical fixation could be explained by the growing understanding of the anatomical 
basis of shoulder function and the development of the angle stable plate systems, together with the 
cumulatively increased experience of surgeons to fix even the more complex 4-part PHF (219).  
The overall detected complications in this study were 27.3% with the overall complication rate of 
the PHILOS plate irrespective of the fracture classification higher than the overall complication 
rate of arthroplasty (28.8% vs. 22.7%). When calculating the overall complication rate in relation 
to the fracture type, complications were more dominant in 4-part fractures (40.5%) than in 3-part 
fractures (18.2%), which is logically explained by the more complex pattern of the 4-part PHF.  
Further analysis of the complication rate recorded for 4-part PHF showed that the PHILOS treated 
4-part fractures had more complications than the cases treated with arthroplasty. This relatively 
low complication rate of arthroplasty, particularly RSA, could be explained by the absence of bone 
union complications in this type of treatment since, in arthroplasty, the fractured humeral head is 
replaced with the prosthesis. However, also arthroplasty has its specific complications, such as 
instability and dislocation.  
 
In this study, among PHILOS treated 4-part fractures, 11 of 16 cases (68.8%) had at least one 
complication. The most frequent complication that occurred among 4-part fracture patients was 
the loss of reduction (mainly varus angulation) (Table 10). Identification of loss of reduction as 
the most common complication following PHILOS comes in line with what was previously 
reported by Haasters et al. (75) and Sproul et al. (17). Arthroplasty treated cases in this study were 
mostly 4-part fractures, with a complication rate of 19% (4 out of 21 cases). The arthroplasty 
complication rate in this study falls within the wide range previously reported in the literature 
(14% to 75% (220) and 19% to 68% (221)), and even below the range reported in Westermann et 
al. (222), who described a complication rate of RSA of 27.4%. The regression model in this study 
showed that 4-part PHF patients treated with ORIF had nine times the odds of suffering from a 
complication when compared to 4-part PHF patients who were treated with arthroplasty.  
However, in this study, the complications in arthroplasty cases were commonly associated with 
revision surgeries. For example, in 4-part PHF, all 4 arthroplasty cases with complications needed 
revision surgery, while only five cases out of eleven 4-part PHILOS treated cases with 
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complications needed revision surgery. This finding shows that complications after angle stable 
plate osteosynthesis are in their largest part less severe than after arthroplasty. Although the loss 
of reduction could frequently end with decreased range of motion and unfavorable functional 
outcome (81), the decreased range of motion in elderly patients could be less critical and could be 
partially accepted, provided that the patients' daily activity can be accomplished without pain 
(223).  
Nearly all 3-part PHF cases in this study were treated with PHILOS (43 out of 44), which showed 
fewer postoperative complications (7 out of 43) than PHILOS after 4-part PHF. The most frequent 
complication reported in the 3-part PHF was screw cut-out followed by infection and loss of 
reduction with one case reporting avascular necrosis of the humeral head. The frequency of screw 
cut-out shown in this study as the most common complication come in line with the previous 
conclusion of Kevin et al. (78), which is further confirmed with the study outcome of Plath et al. 
(224). The high rate of screw cut-outs could be explained by the presence of osteoporosis and 
decreased bone stock in the humeral head. Also, screws cut-out occurrence could be linked to 
delayed PHF healing as a sequence of loss of reduction, which leads to the projection of the upper 
screws into the joint (76, 88). Therefore, enhancing bone healing in PHF is strongly needed to 
reduce the complication rate and its sequences as well as to improve the patient outcome, which 
in turn is expected to decrease the total treatment costs.  
 
Gender differences and length of hospital stay 
The study further yielded several interesting observations and findings. For instance, as reported 
in the literature, the average female-male incidence for PHF in patients above 60, is around 3:1 
(36, 47, 225, 226). However, the overall female-male incidence in this study was 62 females and 
25 males, which represents about 2.5:1. The observed mild difference could be explained by the 
fact that the incidence was calculated for only the surgically operated cases and not for the total 
PHF cases.  
Another critical aspect to investigate was the hospital stay of patients included in the study. 
Analyzing hospital stay showed a slight difference with no statistical significance between 
PHILOS plate fixation and arthroplasty group, with a mean length of stay of 10 ± 7.95 days for 
PHILOS compared to 11 ± 7.32 days for arthroplasty. The duration of hospital stay in this study 
was quite similar to previously published data showing no significant difference between PHILOS 
and arthroplasty groups in elderly patients (227). This has been further confirmed in open PHF in 
the elderly, where no significant difference in the length of stay between PHILOS and arthroplasty 




Revision surgeries were more prevalent in 4-part fractures 
The overall revision surgeries in this study were reported in 13 out of the total of 88 PHF, 
representing about 14.8 %. These numbers are slightly better than the previously reported overall 
revision rate in the literature, which was 15.6% (229) and 17.6% in reversed shoulder arthroplasty 
(230). Interestingly, among those 13 cases, the overall revision rates after arthroplasty were higher 
(23%) than after ORIF with PHILOS (12%). Revision surgery in case of arthroplasty is considered 
technically demanding and mostly results in a worse outcome than found after primary surgery 
(231). As stated above, complications after arthroplasty can mainly be classified as serious and 
frequently need revision surgery. In this study, all five cases of arthroplasty with complications 
needed revision surgery, compared to only 8 out of 19 in the PHILOS group.  
In this study, the revision surgeries were more prevalent in 4-part fractures, with 9 out of all 13 
revision surgeries. This high revision rate for the 4-part fracture explains the great importance of 
proper treatment choice for each patient in order to decrease the complication rate and hence 
decrease the potential revision rate. 
According to the direct results obtained in this study, the choice of arthroplasty to treat 4-part PHF 
showed a lower short-term complication rate, albeit a higher revision rate in comparison with the 
PHILOS. Moreover, it has been reported that the long term results of ORIF with the PHILOS 
showed a better functional outcome than arthroplasty (31). Although arthroplasty has initial 
potential benefits such as less postoperative joint pain, the  range of motion has been reported to 
be unfavorable, especially in the long-term follow up (18, 37, 71, 232–234). After PHILOS 
osteosynthesis, a continuous functional improvement over time could be observed, especially over 
the first postoperative year, which could end with a better outcome in the long term follow-up 
(149). Therefore, active patients with sufficient bone quality and high functional demand could 
gain benefits from PHILOS plate fixation, which preserves the natural humeral anatomy and has 
a better outcome in the long-run (31). In this context, therapeutic approaches to enhance bone 
healing in elderly patients could overcome the known high complication rate of PHILOS treatment 
of the 4-part PHF and could ensure better results, which could help in shifting more 4-part fracture 
patients towards the PHILOS side. Thus, improving the outcome of osteosynthesis for this group 
of patients would be a significant step forward in trauma care. 
Developing and initiating a trial to analyze Iloprost treatment in PHF patients  
One of the main goals of this study was to propose a possible therapeutic strategy to improve the 
outcome for elderly patients undergoing angle stable plate osteosynthesis for PHF. As stated above 
in detail, complication rates in these patients are tremendously high. A potential treatment strategy 
77 
 
to improve clinical outcomes for these patients is promoting fracture healing in PHILOS treated 
patients via the utilization of immunomodulatory therapy. Achieving rapid healing with better 
functional outcomes could help elderly patients to restore their regular daily activity. Moreover, 
with an approach to improve fracture healing, one could avoid possible revision surgery in 
PHILOS treated patients, which in turn could decrease both direct and indirect treatment costs of 
PHF. Such an immunomodulatory therapy strategy is expected to promote healing by controlling 
the initial inflammatory phase in the bone healing process. This phase is known to be of high 
amplitude and long duration in the elderly due to an over-reactive immune response (101, 120, 
127). Local Iloprost application to the fracture site was successfully evaluated as a potential 
immunomodulatory agent in preclinical animal models showing a positive bone healing effect 
(100). Therefore, translating this preclinical data into the clinic is considered to be a beneficial 
treatment option for PHF patients.  
Clinical development strategy  
Choice of the inclusion and exclusion criteria 
The designed clinical trial is a Phase I/IIa; therefore, safety is a significant concern as a primary 
endpoint; the study has been designed with precautions to ensure the participants' safety. The 
inclusion criteria have been chosen to select the specific targeted population with PHF, which 
frequently suffers from bone healing complications. The selected participants' age is from 60 to 
80 years old. Patients in this age range are prone to an unfavorable immune response, which can 
lead to delayed or nonunion (100, 107, 126). Therefore, these patients exhibit a high medical need 
for a biological solution and are a suitable patient cohort for the application of this 
immunomodulatory intervention. Further inclusion criteria have also been chosen based on 
discussions with the BfArM to ensure participants' safety, such as including healthy participants 
(score Ⅰ) or participants with only mild systemic disease (score Ⅱ) according to the criteria of the 
American Society of Anesthesiologists score (ASA).  
Similarly, the exclusion criteria of the designed study have been chosen cautiously to ensure a 
high-quality study protocol. The exclusion criteria can be divided into three main categories; 
firstly, safety exclusion criteria, where the exclusion criteria have been extended to involve any 
contraindication and precaution to Iloprost usage. Therefore, any patient who may be at risk from 
Iloprost usage will be excluded from the trial. Secondly, exclusion criteria that protect participant 
rights and dignity according to the European Parliament and council and the declaration of 
Helsinki (140, 141) are respected. Lastly, the exclusion criteria to assure valid outcome data aiming 
to minimize any confounders for the outcome parameter, such as previous humerus fracture, 
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deformity, or surgery have been included. The patients with previous humerus fracture, deformity, 
or surgery will be excluded from the study because these pathologies would have an influence and 
bias with respect to the functional outcome scores, which are secondary endpoints. 
Determining the dose regimen (duration of treatment, formulation, and method of delivery)  
The main aim of the planned clinical trial was to evaluate both the safety and efficacy of a local 
application of Iloprost at the site of PHF to promote bone healing. In the preclinical work 
performed on the local application of Iloprost in fractures, Iloprost was applied in a fibrin delivery 
system to delay the release of the drug locally (100). This delayed release of Iloprost was essential 
so as not to compromise the initial inflammatory phase of bone healing that has a significant role 
in the healing process by initiating the healing cascade (106). Normally, this initial inflammatory 
phase has been seen to reach its peak within the first 24 hours following fracture and then decline 
(107). However, at the same time, a prolonged or high amplitude inflammatory phase is harmful 
and inhibits bone healing (100). Not only the timing of applying Iloprost to the fracture site is of 
relevance, but also the mode of local release has a significant influence on the benefit profile of 
the drug. The preclinical data provided strong evidence of the benefits of administering Iloprost in 
a delayed-release system (100). 
However, mixing Iloprost with fibrin outside the body is considered a manufacturing step that 
could create a new drug with new properties. According to § 13 AMG (144) and § 5 of the GCP-
V (143), new manufacturing permission, new labeling, and full quality control documents for the 
new drug would thus be needed. This manufacturing permission process is costly, time-
consuming, and complicated.  
Therefore, another delivery method for Iloprost was developed. Iloprost will be administered via 
a catheter that will be inserted at the end of the surgical procedure. The application of Iloprost 
locally via a catheter inserted into the fracture site during the surgical procedure is considered a 
feasible and straightforward method not only to deliver Iloprost directly to the fracture site but 
also to control its dose and infusion rate. Iloprost will be infused through the inserted catheter over 
24-hours starting after the first day (24 ± 2 hours) postoperatively after ORIF. The reason for 
waiting for the first 24-hours postoperatively before starting the infusion is to maintain the initial 
inflammatory phase of bone healing, which represents a significant role in initiating the bone 
healing cascade (105).  
Target population age choice  
The age group in the planned trial includes patients from 60 to 80, who have reported good health 
status. Iloprost is expected to be beneficial in elderly patients as this group is known to have a high 
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risk of delayed healing due to their experienced immune system (100, 107, 126). Therefore, these 
patients exhibit a high medical need for a biological solution and are a suitable patient cohort for 
the application of this immunomodulatory intervention. 
The link between the immune system in the elderly and the bone healing process has been 
previously shown (100, 101, 103). Both bone cells and immune cells originate from common bone 
marrow progenitor cells and share common cell receptors; furthermore, immune cells can 
differentiate into osteoclasts (235). Osteoblasts have the ability to control osteoclasts and influence 
various immune cells as well as hematopoietic stem cells through their ability to release receptor 
activator of nuclear factor κB (RANK) ligand and various mediators (236–238). It has been 
established that the immune system affects the turnover of bone through specific mediator receptor 
interaction (239–241). This effect has been established on physiological bone turnover as well as 
in pathological conditions as in the case of fragility fractures (104).  
Cytotoxic T cells such as Terminally Differentiated Effector Memory CD8+T (TEMRA) cells have  
proven to play a crucial role in controlling bone cells through specific cytokines that control the 
osteoclasts via specific RANK on the cell surface (118). These cells release RANK-ligand that is 
capable of stimulating osteoclasts and hence increasing bone resorption, which, as a result, delays 
the healing process (119). The link between CD8+T (TEMRA) cells and the delayed union has also 
been further proved through the finding of a high population of CD8+T (TEMRA) cells in the 
delayed bone healing fracture site (109, 120). Similarly, fractures in an animal model with a low 
population CD8+ show enhancement of bone healing process (101). Moreover, CD8+T (TEMRA) 
cells were enriched in fracture hematoma; these cells were the major producers of interferon 
ɣ/tumor necrosis factor α, which inhibit osteogenic differentiation and survival of human 
mesenchymal stromal cells (101). Alternatively, CD4+T cells, especially the T regulatory (Treg) 
subtype, showed a positive impact on both wound and bone healing (121–125). Moreover, an 
animal model with a high population of (Treg) showed a higher bone density with decreased bone 
resorption and improved bone healing capacity (121–125).  
In aged patients, the CD8/ CD4 ratio is unbalanced in favor of the CD8+ T cells (242), which 
reveals them as potential candidates for a delayed and insufficient healing of musculoskeletal 
injuries. These patient groups are prone to an advert early immune response after a musculoskeletal 
injury and particularly long healing times after standard care surgical procedures. The cellular 
difference between the young and old population strengthens this assumption, as with aging and 
the continuous exposure to pathogens, the memory T cell population increases. The negative effect 
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of the aged immune system has been proven by improving the bone healing after a rejuvenation 
of the aged immune system (100, 105, 243). 
Iloprost is expected to reduce the risk of delayed bone healing in fracture patients with a potential 
dysregulation of the immune reaction and altered immune cell compositions. Moreover, Iloprost 
reduces the TNF-α and IFN- γ secretion of T cells and further supports macrophage polarization 
towards an anti-inflammatory type. In other words, Iloprost downregulates the initial inflammatory 
phase that is known to be of high amplitude and long duration in this specific age group due to an 
overreactive immune response (101). As such, the product is expected to exert an 
immunomodulatory effect in enhancing bone regeneration in elderly patients with bone fracture.  
The clinical trial approval process  
In order to obtain the necessary approvals for the clinical trial, an application was prepared and 
submitted to both the competent regulatory authority (BfArM) and the ethics committee (LAGeSo) 
in Germany. The entire approval process for obtaining the regulatory permissions and approval 
for the Iloprost study was completed as part of this study. The process included establishing the 
study protocol, preparing and completing all of the required documents as well as addressing the 
raised questions by the authorities in a scientific discussion. The clinical trial application was 
submitted to the ethics committee in April 2019, and the (BfArM) in May 2019.  
The ethics committee comments were focused on the ethical aspect of conducting the clinical trial 
and are related to either formal issues such as completeness of the study documents according to 
the AMG/GCP-V(143, 144) or concerns over the content of the patient information sheet, 
informed consent, or study insurance. The second aimed at warranting that the content of these 
documents is simple and understandable for all patients with all potential risks and side effects 
mentioned in detail. Another critical point was to ensure that the patients´ data protection and 
patient rights to withdraw their consent without any consequences were described in the consent 
form.  
The BfArM role is to inspect the clinical trial design aspects and the relevance of the design 
parameters to the therapeutic concept being investigated. The authority raised concerns over the 
technique used for the local application of the Iloprost, in particular, whether the use of 
intraoperative catheters would bring additional risks for the patients. Moreover, the authority asked 
for additional safety considerations related to the suitability of the calculated dose, local tolerance 
of the investigational drug, and the timing of its application to the fracture site. Another concern 
was to ensure that all the potential contraindications to the drug were listed as exclusion criteria 
while ensuring the reporting of any possible potential side effects or toxicity with a causal 
relationship to the investigational product.    
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All comments and questions raised by the authorities, either the ethics committee or BfArM, were 
addressed adequately, depending on the previously conducted preclinical studies and through deep 
literature research to show the safety and the efficacy of the investigational drug in the planned 
study. Moreover, the positive risk-benefit assessment of using the investigational drug in this new 
clinical indication was shown. The trial design has since been revised, and additional data has been 
provided to address the outlined concerns with greatest attention to details, while maintaining 
patient safety as the first and utmost priority. The clinical trial approvals were obtained in 
November 2019.  
Concluding Remarks and Future perspectives 
The choice of the proper treatment method for PHF in the elderly is a difficult task, and a clear 
consensus on the treatment of choice is currently lacking (67–69). The Cochrane review in 2015 
concluded that the evidence is insufficient to decide the proper intervention for PHF (70). Studies 
that attempted to solve this ambiguity rather collected further evidence of uncertainty (71). In this 
retrospective study, we aimed at providing important clues that could help the decision-making 
process of choosing the most suitable treatment option for this complex fracture. In our cohort 
about 75% of the surgically treated PHF patients aged 60 or above were treated with PHILOS. The 
overall complication rate of the PHILOS irrespective of the fracture classification was higher than 
the overall complication rate of arthroplasty (28.8% vs. 22.7%). Patients undergoing fixation 
would clearly benefit from potential therapeutic approaches to improve their outcome. We used 
these observations to select the target patient population for a prospective pilot clinical study to 
investigate the role of local application of the immunomodulator Iloprost at the fracture site to 
improve bone healing. Further efforts by the scientific and clinical community could be directed 
toward establishing a comprehensive treatment guidance for patients suffering from PHF.   
 
Study limitations 
This study has several limitations, such as being a retrospective study done in a tertiary academic 
hospital that receives more complicated cases referred from other hospitals. Moreover, the 
functional outcome assessment has not been included in this retrospective search. In addition, the 
follow-up time was relatively short. Data on all surgically treated PHF patients were collected 
from the digital hospital information system (SAP, Walldorf, Germany). The patient's files were 
searched for all relevant data before and after surgery and at follow-up visits. However, functional 
outcome measures were not continuously documented among all patients, while detailed 
information on the patient's secondary diagnoses (the complete set of comorbidities) was 
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somewhat deficient. As already described in the chapter Materials and Methods, patients with 




Chapter 5 : Summary  
Traumatic bone fracture is one of the most common injuries worldwide. In Germany, about 1.6 
million bone fractures have been reported per year. Proximal humerus fracture (PHF) is considered 
to be one of the most common traumatic bone fractures in the elderly population (>65 years old) 
and is ranked third after hip and distal radial fracture. The incidence of PHF is expected to triple 
in the next three decades because of the cumulative aging of the world population. This high 
incidence in old age is linked to osteoporosis and is more common in females, who represent 75% 
of the cases. Because of poor bone quality and high incidence of complications in the postoperative 
follow-up, the treatment of PHF is expected to be a significant challenge in the near future. 
PHF is mainly classified according to the Neer classification into four main classes, which are 
derived from the involvement of the four main anatomical parts of the proximal humerus: head, 
humeral shaft, greater tuberosity, and lesser tuberosity. Fractures are considered displaced if there 
is a fragmental displacement of one cm or angulation of more than 45 degrees. The more the 
advancement of the fracture class from one to four, the more complex is the fracture pattern.  
The treatment of PHF remains one of the unsolved orthopedic problems, also mainly due to the 
absence of clear evidence-based guidelines for treatment. The recommended treatment of 
displaced patients suffering from 3-part and 4-part PHF is mainly surgery. Currently, surgeons 
rely on a compilation of factors when deciding on the most suitable management strategy, which 
is, apart from the classification, the degree of fracture comminution, patient bone quality 
(osteoporosis), patient age, physical capacity, and functional demand of the patient. The main 
available surgical options used in the treatment of PHF are angle stable plate osteosynthesis (ORIF, 
e.g., with the PHILOS, Synthes, Switzerland) and arthroplasty. Unfortunately, the outcome after 
PHF surgery exhibits a high complication rate that differs from one study to another and ranges 
from 9.7% to 57% after ORIF and 14% to 68% in arthroplasty treated patients. The current 
treatment strategy for PHF does not involve pharmacologic treatments since no drugs exist that 
could stimulate bone healing in fractured patients sufficiently, especially compromised elderly 
patients.  
Using an immunomodulatory therapy as a novel strategy could be of potentially beneficial 
therapeutic value as a new strategy for treating elderly PHF patients with an experienced immune 
system, which has been shown to compromise bone healing. Such therapy is expected to reduce 
the risk of delayed bone healing in fracture patients with a potential dysregulation of the immune 
reaction and altered immune cell compositions at the fracture site via downregulating CD8+ 
cytotoxic T cells, which have a potentially unfavorable effect on bone healing. Moreover, an 
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immunomodulatory therapy could reduce the cytokine secretion of T cells and further support 
macrophage polarization towards an anti-inflammatory M2 type. 
The primary study question of this thesis was which group of patients in the elderly population 
with PHF have the least favorable clinical outcomes after surgical intervention. In addition, the 
study aimed at proposing a potentially beneficial drug that may enhance bone healing in patients 
treated with ORIF. The thesis was divided into two parts. The first focused on a literature review 
and retrospective medical record analysis. This medical record analysis was conducted to measure 
the outcome of surgical management strategies, including complication and revision rates, of the 
two most commonly performed surgical procedures (angle stable plate ORIF and arthroplasty) in 
elderly patients with PHF. The complications included in this study were all of Grade 2 or more 
according to the surgical complication classification described by Dindo et al., which includes any 
complication that may need medical treatment (except simple medications such as antipyretic or 
analgesic) or prolonged hospital stay. It also includes all complications that are considered major 
and need active management and/or further surgical intervention. A retrospective medical record 
review analysis was performed at the Center for Musculoskeletal Surgery of the Charité - 
Universitätsmedizin Berlin for all primary treatments of PHF between March 2017 and June 2018. 
All surgically treated patients aged 60 years old or older, who were operated with either ORIF 
(PHILOS) or arthroplasty with a follow-up period of at least six months were included. This 
enabled us to identify the group of ORIF patients with the highest complication rate that would 
benefit the most from novel therapeutic approaches. The second part focused on developing a 
scientifically sound clinical and translational strategy for a novel immunomodulatory approach 
that may improve the healing outcomes for the identified group of patients.  
A clinical trial was designed to investigate the local application of Iloprost as an 
immunomodulatory agent for PHF healing. The study aims at investigating the safety of the drug 
and its ability to improve healing outcomes for these patients by reducing a prolonged and 
excessive pro-inflammatory reaction. The clinical testing of such a novel therapeutic approach 
requires the translation of generated pre-clinical knowledge into a sound clinical strategy. The 
work performed within the framework of this thesis focused on the utilization of previous 
nonclinical studies of the BCRT group to determine the clinical testing strategy in PHF patients.  
In the retrospective analysis, 105 surgically treated PHF patients who underwent operative 
treatment were screened and 88 PHF in 87 patients with a mean age of 72.9 years included. The 
study population had an expected higher proportion of females (70.4%). According to the Neer 
classification, 50% of the patients suffered from 3-part fracture, while 42% suffered from 4-part 
fractures. The majority of the study patients (75%) were treated with ORIF. The overall 
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complication rate was 27.3%. As expected, the incidence of complications increased with more 
displaced fracture fragments (higher fracture type according to the Neer classification). In 3-part 
PHF, patients treated with the PHILOS had a complication rate of about 16.3%, while ORIF treated 
patients with 4-part PHF exhibited a complication rate of about 68%. The 22 patients treated with 
arthroplasty had an overall complication rate of about 19%. It should be mentioned that all 
arthroplasty prostheses used in this study were reversed shoulder arthroplasty, with the exception 
of only three cases, which were of the hemiarthroplasty prosthesis type. All of these three 
hemiarthroplasty cases were used to treat 4-part PHF and ended with complications, revised later 
on with total shoulder arthroplasty. The complications seen in the hemiarthroplasty cases were 
instability, dislocation, and infection.  
The logistic regression model showed that 4-part PHF patients had about seven times the odds of 
suffering from a complication compared to patients with 3-part PHF, regardless of the received 
surgical intervention (PHILOS or arthroplasty). Treating 4-part PHF patients with angular stable 
ORIF had an odds rate of about nine times when compared to the odds rate of arthroplasty. These 
results showed that 4-part PHF had the highest complication rate, particularly when treated with 
ORIF. This relatively low complication rate of arthroplasty, especially RSA, could be explained 
by the absence of bone union complications in this type of treatment since, in arthroplasty, the 
fractured humeral head is replaced with the prosthesis. Whereas arthroplasty also has its specific 
complications, such as instability and dislocation, in this study, the complications in arthroplasty 
cases were more frequently associated with the need for revision surgery. For example, in 4-part 
PHF, all four arthroplasty cases with complications needed revision surgery, while only five cases 
out of eleven 4-part PHILOS treated cases with complications needed revision surgery. 
Moreover, revision surgery in the case of arthroplasty is considered technically demanding and 
mostly results in an even less satisfactory outcome than found after primary surgery. Unlike 
shoulder arthroplasty, the treatment of complex PHF in the elderly with angle stable plate 
osteosynthesis has the advantage of continuous functional improvement over time, especially in 
the first postoperative year, which has been shown to be accompanied by a better outcome in the 
long-term follow-up. In this context, providing a specific treatment that could improve bone 
healing and enhance the overall outcome of PHF undergoing ORIF with an angular stable plate 
fixation would be of great value for PHF patients. Therefore, Iloprost as an immunomodulatory 
therapeutic agent has been identified, and a trial was designed based on its properties and previous 
results. The trial design development and the process for obtaining all regulatory permissions and 
approvals for the Iloprost study were completed as part of this research. The complete clinical trial 
application was submitted in May 2019 to the Federal Institute for Drugs and Medical Devices 
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(BfArM). After responding to several questions raised by the authorities in a scientific discussion 
in two iterations, the final approval for the clinical trial was obtained in November 2019. The trial 
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